

2026
춘계심혈관통합학술대회
& ACC ASIA 2026
ACC ASIA 2026 TOGETHER WITH KSC SPRING CONFERENCE

Royal Platinum Sponsor

BORYUNG

2026 춘계심혈관통합학술대회 & ACC ASIA 2026 | ACC ASIA 2026 TOGETHER WITH KSC SPRING CONFERENCE

2026
춘계심혈관통합학술대회
& ACC ASIA 2026

ACC ASIA 2026 TOGETHER WITH KSC SPRING CONFERENCE



GYEONGJU, KOREA
Hwabaek International Convention Center (HICO)
17 - 18 APRIL 2026



LIVE LIGHTER™ with Wegovy®

주 1회 비만 치료제의 시작, 위고비®^{1,2} 한국인 포함 임상 근거 기반의 체중 감량^{3,4}

* [STEP 5] 104주 후 평균 체중 감량 약 16%: The estimated mean weight change at week 104 was approximately -15.2% with semaglutide 2.4 mg (ETD -12.6; 95% CI -15.3 to -9.8, p<0.0001) in treatment policy estimand (observed in-trial data, intention to treat) and approximately -16.7% with semaglutide 2.4 mg (ETD -16.0; 95% CI -18.6 to -13.5) in trial product estimand when taken over 104 weeks adjust to a reduced energy diet and increased physical activity.

STEP 5[†]

≥20%

체중 감량
연구 참여 성인 환자
약 3명 중 1명 달성*

SELECT⁶

20%

주요 심혈관계 사건
위험 감소*

* AI generated image

[Study design of STEP 5] STEP 5는 성인 비만 환자를 대상으로 104주간 진행한 3상 임상시험(비만증, 위약 대조, 무작위 배정) 연구입니다. 전체 304명의 환자가 위고비® (Semaglutide) 2.4 mg 투여군 152명, 위약군 152명으로 1:1 무작위 배정되었습니다. 위고비® (Semaglutide) 2.4 mg 투여군은 0.25 mg/주부터 투여하여 첫 16주 치까지 점진적으로 용량을 증량하였고, 이후 104주 치까지 유지 용량(2.4 mg)을 투여하였습니다. 이후 7주간(111주 치까지) 추적관찰을 진행하였습니다. 위고비® (Semaglutide) 2.4 mg 투여군 및 위약군 모두 생체 중량(500 kcal/일 식사 + 150분/주 신체 활동)을 병행하였습니다. [주요 평가 변수(104주)] • 공통 주요 평가 변수: Baseline 대비 체중 변화 / 5% 이상의 체중 감소 달성, * 2차 하위효과 평가 변수: 10% 및 15% 이상의 체중 감소 달성 / 허리 둘레 및 수축기 혈압 변화, * 2차 보조적 평가 변수: 20% 이상의 체중 감소 달성 / 체중, BMI, HbA_{1c}, 관상 혈관, 이완기 혈압, 지질, C-reactive 단백질 변화 / (Baseline-52주) 체중, BMI, 허리 둘레 변화 및 5%, 10%, 15%, 20% 이상의 체중 감소 달성

[Safety profile of STEP 5] STEP 5 임상시험에서 투여 중단으로 인한 이상반응은 위고비® (Semaglutide) 2.4 mg 투여군의 5.9% (9/152), 위약군의 4.6% (7/152)에서 보고되었습니다. 가장 빈번하게 보고된 이상반응은 위장장애(오심, 설사, 구토, 변비)로서, 위고비® (Semaglutide) 2.4 mg 투여군의 62.2% (125/152), 위약군의 53.9% (82/152)에서 보고되었습니다.*

[Study design of SELECT] SELECT는 심혈관계 질환이 있고 과체중 또는 비만한 성인 환자를 대상으로 한 다국가, 이중 눈가림, 위약 대조, 무작위 배정 3상 연구입니다. 전체 17,604명의 환자가 위고비® (Semaglutide) 2.4 mg 투여군 8,803명, 위약군 8,801명으로 1:1 무작위 배정되었습니다. 위고비® (Semaglutide) 2.4 mg 투여군은 0.24 mg부터 투여하여 대 4주간 용량 증량(0.5, 1.0, 1.7, 2.4 mg)을 통해 16주 후 목표 용량(2.4 mg)에 도달하였습니다. 위고비® (Semaglutide) 2.4 mg 투여군은 환자가 개별화된 건강한 생활 방식에 대한 상담(식이요법 및 신체활동 포함) 및 심혈관계 위험 요인의 관리를 포함하는 현행 표준 요법을 병행하였습니다. [주요 평가 변수] 1차 복합 평가 변수: 무작위 배정 이후 3-POINT MACE (심혈관계 질환 사망, 비심혈관계 심근경색 또는 비심혈관계 뇌졸중)의 첫 발생까지의 시간(1차 분석은 최초 MACE까지의 시간)에 대해 위약 대비 위고비® (Semaglutide) 2.4 mg 투여군의 우월성을 평가함), 2차 복합적 평가 변수: 무작위 배정 이후 3-POINT MACE의 발생까지의 시간(심혈관계 뇌졸중 제외), 3차 평가 변수에 대해 동등적 우월성을 입증해야만 2차 복합적 평가 변수의 2차 보조적 평가 변수를 검증할 수 있음, 주요 2차 평가 변수: 심혈관계 질환 사망 / 모든 원인의 사망 사망, * 1차 2차 평가 변수: 치명적 또는 비치명적 심근경색 / 치명적 또는 비치명적 뇌졸중

[Safety profile of SELECT] SELECT 임상시험에서 투여 중단으로 인한 이상반응은 위고비® (Semaglutide) 2.4 mg 투여군의 33.4% (2,941/8,803), 위약군의 36.4% (3,204/8,801)에서 보고되었습니다. SELECT 임상 시험에서 투여 중단으로 인한 이상반응은 위고비® (Semaglutide) 2.4 mg 투여군의 16.6% (1,461/8,803), 위약군의 8.2% (718/8,801)에서 보고되었습니다.*

* p<0.001 for odds ratio for the 5%, 10% and 15% thresholds; the 20% threshold was not part of the statistical testing hierarchy. * 주요 심혈관계 사건(심혈관계 질환 사망, 비치명적 심근경색 또는 비치명적 뇌졸중) 위험 감소: HR 0.80 (95% CI: 0.72 to 0.90, p<0.0001).

BMI, body mass index; CI, confidence interval; ETD, estimated treatment difference; HbA_{1c}, glycated hemoglobin; HR, hazard ratio; MACE, major adverse cardiovascular events.

References 1. 위고비® 프리필드 펜 0.25, 0.5, 1.0, 1.7, 2.4 mg (세미글루티드). 국내 제품 설명서. Available via: <https://nedrug.mfds.go.kr/jsp/CCBB801/getItemDetailCache?cacheSeq=202301384updateTs2024-10-29%2017:46:04.705077b>. Accessed on 26 Feb 2026. 2. 대한비만학회. 비만의료지침 제정안(2024). 3. Kadowaki T, Isenhardt J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. *Lancet Diabetes Endocrinol*. 2022;10(3):193-206. 4. Mu Y, Bao X, Ellsawitz FG, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2024;12(3):184-95. 5. Garvey WT, Batterham RL, Shattock M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med*. 2022;28(10):2083-91. 6. Lincoff AM, Brown-Fandens K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389(24):2221-32.

[수입의약품-전문의약품] 위고비프리필드펜0.25(세미글루티드), 위고비프리필드펜0.5(세미글루티드), 위고비프리필드펜1.0(세미글루티드), 위고비프리필드펜1.7(세미글루티드), 위고비프리필드펜2.4(세미글루티드)

위고비®프리필드펜에 대한 보다 자세한 내용은 QR 코드를 스캔하시거나 식물의약품안전처 의약품통합정보시스템 (<https://nedrug.mfds.go.kr/>)의 최신 제품설명서를 참조하시기 바랍니다.



노보 노디스케어(주)

서울시 송파구 올림픽로 35길 137. (신천동, 한국광고문화회관 16층)
TEL: 02-2188-8900 FAX: 02-2188-8980 www.novonordisk.co.kr
All right reserved by Novo Nordisk Pharma Korea LTD.



(주)종근당

서울특별시 시대문구 중정로 8 (충정로 3가) TEL: 02-2194-0300
FAX: 02-2194-0369 소비자상담실 : 080-6776-080 (수-신자부담)
<https://www.kdpharm.com/>

NP25SEM000073 Feb 2026



THE 70TH ANNUAL SCIENTIFIC MEETING OF
THE KOREAN SOCIETY OF CARDIOLOGY

2026.10.15(Thu.)-17(Sat.)
Grand Walkerhill Seoul, Korea

대한심장학회 심장학연구재단

2027 춘계심혈관통합학술대회

2027 Annual Spring Scientific Conference of the KSC with Affiliated Cardiac Societies

APRIL 16(Fri.)-17(Sat.), 2027
BEXCO, Busan

Operating Hours

Category	Open - Close	Venue
Registration	4/17(Fri.) 08:00-17:00	1F Lobby
	4/18(Sat.) 07:30-15:30	
Preview Room *Please submit the presentation materials at least 2 hours before.	07:00 - 17:00	2F Rm.201
Exhibition	09:00 - 17:00	1F Exhibition Hall
Cafeteria	09:00 - 17:00	1F Exhibition Hall 3F Lobby
Faculty Lounge	09:00 - 17:00	2F S207



Sponsors

Royal Platinum

BORYUNG

Platinum

AMGEN

ORGANON

Hanmi Hanmi Pharm.

NOVARTIS

SAMJIN SAMJIN PHARM.

SkyLabs

Gold

VIATRIS

Pharm
CELLTRION
daewon
Pharmaceutical

Daiichi-Sankyo
DAEWOONG
www.daewoong.co.kr

JW Pharmaceutical

YUHAN

CKD

Silver

Bayer

inno.N

Boehringer
Ingelheim

DAEWOONG

Bronze

Bristol Myers Squibb
Pfizer

Bristol Myers Squibb

GSK

sanofi

YOOYOUNG

ILDONG

SK chemicals


HANJOK

DONG-A ST


Guide Map

● 출결등록기계(평점)


1F



2F



3F



Highlight Program

4/17(Fri.)

08:40-09:25

300A

ACC ASIA

Plenary 1

✓ INOCA/ANOCA: An Emerging Global Issue

4/17(Fri.)

13:20-14:00

300B

KSC

Suh, Soon Kyu Memorial Lecture

4/17(Fri.)

16:05-16:50

300A

ACC ASIA

Plenary 2

✓ Leveraging AI in EMR and Beyond

4/18(Sat.)

08:55-09:40

300A

ACC ASIA

Plenary 3

✓ Top Clinical Trials

4/18(Sat.)

14:25-15:10

300A

ACC ASIA

Plenary 4

✓ STEMI Care Delivery: Global Disparities and Solutions

Program at a Glance / Day 1

17 Fri.	ACC ASIA 2026			
	103	202	205	300A
08:40-09:25			ENG Multimodal Imaging 1 (Joint Session with Korean Society of Echocardiography) Mitral Stenosis in the Modern Era: Rheumatic Legacy, Calcific Challenge, Percutaneous Promise	ENG Plenary 1 INOCA/ANOCA: An Emerging Global Issue
09:35-10:20	ENG Oral Abstracts Presentations 1	ENG Special Topics 1 Pediatric Cardiology: Prevention, Kawasaki Disease, and Lifelong Risk	ENG Multimodal Imaging 2 (Joint Session with Korean Society of Echocardiography) Seeing Through the Thickness: The Power of Multimodality Imaging	ENG Cardiac Arrhythmias 1 Regional Differences in AFib Management
10:30-11:15	ENG Oral Abstracts Presentations 2	ENG Special Topics 2 Women's Heart Disease: Hormones, Rhythm, and Risk	ENG Heart Failure and Cardiomyopathies 1 (Joint Society Session with Korean Society of Heart Failure) Heart Failure Management: Devices, AI, and Emerging Therapies	ENG Valvular Diseases and Structural Interventions 1 Valvular Interventions: Lessons from Challenging Cases
11:25-12:10	ENG Oral Abstracts Presentations 3	ENG Special Topics 3 Genomics and Genetics in Cardiovascular Disease: From Cardiomyopathy to Dyslipidemia	ENG Heart Failure and Cardiomyopathies 2 (Joint Society Session with Korean Society of Heart Failure) Obesity, Inflammation, and Heart Failure: Treating the Whole Disease	ENG Valvular Diseases and Structural Interventions 2 Updates in the Guidelines: What to Know
12:20-13:00			KSC Scientific Session [Samjin] Contemporary Approaches to Managing Pediatric Pulmonary Arterial Hypertension	KSC Scientific Session [Organon] Redefining Lipid Control with Atorvastatin Plus Ezetimibe for Early and Optimal LDL-C Reduction
13:10-14:00	Break			
14:00-14:15	Break			
14:15-15:00	ENG Complex Case Discussions 1	ENG Coronary Interventions and Ischemic Heart Diseases 1 AI in Action: Transforming Coronary Intervention From Planning to Precision	ENG Cardiovascular Disease Prevention 1 (Joint Session with Korean Society of Lipid and Atherosclerosis) 2025 Cholesterol Guidelines: Integration and Application in Asia	ENG Heart Failure and Cardiomyopathies 3 Complex Cardiomyopathies: Diagnostic Innovations and Therapeutic Advances
15:10-15:55	ENG Oral Abstracts Presentations 4	ENG Special Topics 4 Cardio-Oncology: Bridging Cancer and Cardiovascular Care	ENG Cardiovascular Disease Prevention 2 (Joint Session with Korean Society of Lipid and Atherosclerosis) Beyond Statins: Novel Therapies For Dyslipidemia and Cardiovascular Prevention	ENG Valvular Diseases and Structural Interventions 3 Asymptomatic Severe Valve Disease: Evidence and Decision-Making
16:05-16:50			ENG Coronary Interventions and Ischemic Heart Diseases 2 (Joint Session with Korean Society of Interventional Cardiology) Breaking Barriers in Complex High-Risk PCI: Innovations and Strategies	ENG Plenary 2 Leveraging AI in EMR and Beyond
17:00-17:45			ENG Coronary Interventions and Ischemic Heart Diseases 3 (Joint Session with Korean Society of Interventional Cardiology) Inside the Vessel: Advanced Imaging and Physiology For Complex PCI	ENG FIT Jeopardy: The Classic Game Show With a FIT Twist!

- The Korean Society of Cardiology
- Korean Heart Rhythm Society
- The Korean Pediatric Heart Society
- The Korean Society of Heart Failure
- Korean Society of Interventional Cardiology
- The Korean Society of Echocardiography
- The Korean Society of Lipid and Atherosclerosis

17 Fri.	2026 춘계심혈관통합학술대회					
	102	104	105	203	300B	300C
08:40-10:10	Basic Research 1 유전자 편집 기술의 원리부터 심혈관질환 임상 적용까지	Myocardial Infarction 1 심근경색증 진단하기 (중재를 중심으로)	ENG Hypertension New Era of Out-of-Office BP Monitoring: Guidelines, Evidence, and Technology	KSHF 1 Modern Drug Therapy for Heart Failure in Real Clinical Practice	Cardiometabolic Syndrome 1 Deconstructing the "Fatty" CKM: Adiposity and Inflammation	Interesting ECG
10:30-12:00	ENG Basic Research 2 From Bedside to Bench: Patient-Derived Samples in Cardiovascular Research	Insurance Issues 심장분야 의료기기 및 혁신SI기술의 국산화와 과제	Pulmonary Hypertension Current Therapeutic Approaches in Pulmonary Hypertension	Cardiac Pathology Tissue Based Approach: Integrated Patho-cardiology Strategies for Immune Checkpoint Inhibitor Myocarditis and Radiation Induced Heart Disease	Cardiometabolic Syndrome 2 RNA Revolution: Silencing the Drivers of CKM Syndrome	KHRS1-AF Atrial Fibrillation: State-of-the-Art 2026
12:20-13:00	Scientific Session [Chong Kun Dang] Evolution of Cardiovascular Care: Redefining Strategies for Hypertension and Heart Failure		Scientific Session [Hanmi] Early Combination Therapy: A Paradigm Shift in CVD Treatment	Scientific Session [Novartis] Beyond LDL-C Reduction: Consistent Control	Scientific Session [Amgen] The Evolving Role of Evolocumab in ACS: Optimizing Lipid Management and Cardiovascular Outcomes	Scientific Session [Boryung] Comprehensive Cardiovascular Disease Management
13:10-14:00					ENG 13:10-13:20 Opening Ceremony ENG 13:20-14:00 Suh, Soon Kyu Memorial Lecture	
14:00-14:15	Break					
14:15-15:45	Adult Congenital Heart Disease 1 Pulmonary Arterial Hypertension in Adult Congenital Heart Disease: From Pathophysiology to Management	Myocardial Infarction 2 심근경색증 치료하기 (최신연구를 중심으로)	Women Heart Disease Sex-Based Differences in Emerging Cardiovascular Risk Factors	Cardiovascular Imaging From Cancer Therapy to Cardiac Injury: Clinical and Imaging Perspectives on Cardiotoxicity, Including ICI-Related Myocarditis	KSIC 1 Optimizing Antithrombotic Therapy after PCI in Patients Requiring Oral Anticoagulation	KHRS2-SCD Sudden Cardiac Death
16:05-17:35	Adult Congenital Heart Disease 2 Small Shunt Is Really Simple?	ENG Epidemiology From Evidence to Action: Global Implementation Strategies for CVD Prevention	KSE 1 Echocardiographic Hemodynamics: From Physiology to Clinical Decision-Making	ENG Cardio-Oncology Update on Cardio-Oncology 2026	Healthcare Policy 필수의료 위기 극복을 위한 심뇌혈관질환 관리 체계의 대 전환	KSoLA 1 New Direction of Korean Guideline for Lipid Management

✓ Rare Genetic CVD Session

일시: 4월 17일(금) 오후 2시 15분-5시 35분 | 장소: 경주힐튼호텔 파인룸(1F)

ENG

 English Session

Program at a Glance / Day 2

ACC ASIA 2026				
18 Sat.	103	202	205	300A
08:00-08:45	ENG Oral Abstracts Presentations 5	ENG Valvular Diseases and Structural Interventions 4 Valvular Disease Controversies: Lifetime Management and Therapy Choices	ENG Cardiovascular Disease Prevention 3 Obesity Management in Asia: Medical, Surgical, and Emerging Therapies	ENG Cardiac Arrhythmias 2 Advances in Stroke Prevention For Atrial Fibrillation: Evidence and Innovation
08:55-09:40				ENG Plenary 3 Top Clinical Trials
09:50-10:35	ENG Complex Case Discussions 2	ENG Research Workshop: Part 1	ENG Cardiac Arrhythmias 3 Ventricular Tachycardia in Cardiomyopathy: Mapping, Genetics, and Imaging	ENG Cardiovascular Disease Prevention 4 Global Perspectives on Blood Pressure Guidelines: ACC/AHA, KSH, and JSH
10:45-11:30	ENG Complex Case Discussions 3	ENG Research Workshop: Part 2	ENG Cardiac Arrhythmias 4 Device Therapies in Heart Failure: Innovations and Clinical Impact	ENG Coronary Interventions and Ischemic Heart Diseases 4 Personalizing Antiplatelet Therapy: Risk, Genetics, and Regional Insights
11:40-12:20		ENG Special Topics 5 Women in Cardiology: Pathways to Success and Leadership	KSC Scientific Session [Yuhan] The New Era of Lipid Management: Translating 2026 ACC/AHA Guidelines into Practice with Rosuvastatin Plus Ezetimibe for Intensive LDL-C Targeting	KSC Scientific Session [Celltrion Pharm/Daewon] Strategies for Managing Hypertension
12:20-12:35 Break				
12:35-13:20	ENG Oral Abstracts Presentations 6	ENG Multimodal Imaging 3 Top 3 Innovations or Hot Topics in Multimodal Imaging	KSC Cardio-cerebrovascular Disease Prevention 12:35-14:05 High-Risk Pregnancy and Lifelong Cardiovascular Health: From Early Risk to Prevention	ENG Special Topics 6 Digital Health in Cardiology: AI, Wearables, and Imaging
13:30-14:15	ENG Complex Case Discussions 4	ENG Multimodal Imaging 4 From Leads to Leaflets: Multimodality Imaging in the Diagnosis of Endocarditis		ENG Heart Failure and Cardiomyopathies 4 Acute Heart Failure: Managing Cardiorenal Syndrome and Shock
14:25-15:10				ENG Plenary 4 STEMI Care Delivery: Global Disparities and Solutions
15:20-16:05				ENG Convocation and Closing Ceremony

- The Korean Society of Cardiology
- Korean Heart Rhythm Society
- The Korean Pediatric Heart Society
- The Korean Society of Heart Failure
- Korean Society of Interventional Cardiology
- The Korean Society of Echocardiography
- The Korean Society of Lipid and Atherosclerosis

2026 춘계심혈관통합학술대회						
18 Sat.	102	104	105	203	300B	300C
08:00-09:30	Cardiogenic Shock Modern Management of Cardiogenic Shock	Cardiac Surgery A Deadly Duo: Valvular Heart Disease and Atrial Fibrillation	KSE 2 Imaging-Guided Approach to Cardio-myopathies: From Diagnosis to Treatment Guidance	ENG Vascular Research 1 2026 How to Measure Vascular Health	KSIC 2 Managing Coronary Calcification in PCI	Education Workshop 1 - Arrhythmia Recent Therapeutic Approaches in Arrhythmias
09:50-11:20	Cardiovascular Genome and Precision Medicine Deep Dive to Genetic Testing, What, When, How & Who?	ENG KPHS 1 Rethinking 'Simple' Heart Defects: Advances in Diagnosis and Treatment	ENG KSE 3 Echo on the Frontlines: Here, There, and Everywhere	KSHF 2 Advanced Therapies, Palliation, and Human Dignity in Stage D Heart Failure	Smart Health Human-AI Collaboration in Cardiovascular Digital Health Care: Opportunities, Limits, and Trust	Education Workshop 2 - Hypertension Recent Issues in Hypertension
11:40-12:20			Scientific Session [Daiichi Sankyo/Daewoong] Evidence-Based Management of Atrial Fibrillation and Hypertension	Scientific Session [JW Pharm] Strategic Management for Cardiovascular Prevention: Balancing Efficacy and Safety	Scientific Session [Viatris] From Risk Recognition to Therapeutic Decision: Statin Selection Beyond LDL-C	Scientific Session [Sky Labs] Cuffless BP Monitoring: Evidence to Experience
12:20-12:35 Break						
12:35-14:05	KSoLA 2 Beyond LDL-C: Residual Risk and Competing Priorities	ENG KPHS 2 Left-sided Valve Issues in Congenital Heart Diseases	KHRS3-CIED Optimal Strategies for Cardiac Pacing Therapy: From Physiologic Pacing to Long-Term Complication Management (Case-Based)	Vascular Research 2 2026 How to Manage Peripheral Artery Disease	KSIC 3 Cross Specialty: Cutting-Edge Issues in TAVR 2026	Education Workshop 3 - Heart Failure Diagnosis and Treatment Beyond HFrEF
14:25-15:55	KSoLA 3 Dyslipidemia Management in Special Populations	KPHS 3 Genetic Insights into Pediatric Heart Disease	KHRS4-VT Ventricular Tachycardia	KSHF 3 Imaging in Heart Failure Diagnosis and Treatment [Cross-Specialty]	KSIC 4 심장내과의사와 전공의를 위한 대퇴슬와동맥질환의 기본	Education Workshop 4 - Echocardiography Echocardiograph Update 2026

ENG English Session

Attendance Guide

Registration

For Domestic		
Category	Pre-Registration	On-site Registration
Physician	120,000KRW	150,000KRW
Fellow, Trainee, etc	70,000KRW	90,000KRW
65+	Free	
Others(Free)	International fellows(Submission of application form and a copy of passport required) Undergraduate/graduate students (Student ID must be presented)	

For International		
Category	Pre-Registration	On-site Registration
Academic/Researcher	USD 200	USD 250
Nurse	USD 150	USD 200
Physician	USD 200	USD 250
Physician, Fellow-in-Training/Early Career	USD 200	USD 250
Pharmacist	USD 150	USD 200
Other	USD 150	USD 200

Lunch

① Lunch will be provided at the session rooms during Scientific Sessions.

② Scientific Sessions

Date	Time	Room
4/17(Fri.)	12:20 - 13:00	Rm. 102, 105, 203, 205, 300A, 300B, 300C
4/18(Sat.)	11:40 - 12:20	Rm. 105, 203, 205, 300A, 300B, 300C

Coffee & Concierge Service

Coffee	1F Exhibition Hall	09:00 - 17:00
	2F Faculty Lounge	
	3F Lobby	
Concierge	1F Lobby	

Shuttle Bus

Line 1 : Gyeongju Station(KTX) ↔ HICO
Line 2 : Kensington Resort Gyeongju → Lahan Select Gyeongju Hotel → HICO
Line 3 : HICO → Lahan Select Gyeongju Hotel → Kensington Resort Gyeongju



HICO
Shuttle Bus Stop
Gate 5 Parking Lot

4/17(Fri.)

Line 1 : Gyeongju Station(KTX) ↔ HICO			Line 2 : Kensington Resort Gyeongju → Lahan Select Gyeongju Hotel→ HICO				Line 3 : HICO → Lahan Select Gyeongju Hotel → Kensington Resort Gyeongju			
40 mins	Depart from Gyeongju Station	Depart from HICO	7 mins	Depart from Kensington Resort Gyeongju	Depart from Lahan Select Gyeongju Hotel	Arrival at HICO	7 mins	Depart from HICO	Arrival at Lahan Select Gyeongju Hotel	Arrival at Kensington Resort Gyeongju
1	07:30	14:00	1	07:43	07:50	07:57	1	15:50	15:57	16:04
2	07:50	15:30	2	08:13	08:20	08:27	2	16:50	16:57	17:04
3	09:00	16:40	3	08:43	08:50	08:57	3	17:40	17:47	17:54
4	09:40	18:00	4	09:13	09:20	09:27	4	18:00	18:07	18:14
5	10:30		5	09:43	09:50	09:57				
6	12:00		6	10:53	11:00	11:07				
7	13:20									
8	16:00									

4/18(Sat.)

Line 1 : Gyeongju Station(KTX) ↔ HICO			Line 2 : Kensington Resort Gyeongju → Lahan Select Gyeongju Hotel→ HICO			
40 mins	Depart from Gyeongju Station	Depart from HICO	7 mins	Depart from Kensington Gyeongju Hotel	Depart from Lahan Select Gyeongju Hotel	Arrival at HICO
1	07:30	12:40	1	07:13	07:20	07:27
2	07:50	14:00	2	07:43	07:50	07:57
3	09:00	15:30	3	08:13	08:20	08:27
4	09:40	16:10	4	08:43	08:50	08:57
5	10:30		5	09:13	09:20	09:27
6	12:00		6	10:53	11:00	11:07

*Please note that the required times are subject to change depending on the traffic condition.

평점안내 (Korean Only)

1. 평점

구분	4/17(금)	4/18(토)
대한의사협회	6점	6점
대한내과학회 분과전문의	-	6점
내과전공의 외부학술회의 (학술대회)	2 점	

시간	평점
1시간 미만	인정 불가
1시간 이상 2시간 미만	1 평점
2시간 이상 3시간 미만	2 평점
3시간 이상 4시간 미만	3 평점
4시간 이상 5시간 미만	4 평점
5시간 이상 6시간 미만	5 평점
6시간 이상	6 평점

2. 평점 인정 기준

- 참석하는 세션마다 2회 명찰 바코드 스캔
[회의장 입실(세션시작) 시 1회, 퇴실(세션종료) 시 1회]
- 각 회의장 입구에 설치된 출결등록기계에 입실(세션시작) 시 1회, 퇴실(세션종료) 시 1회 명찰 바코드를 스캔해야 하며, 실 참석 시간에 따라 평점이 인정됩니다.
- 각 회의장 입실 또는 퇴실 시, 1회만 명찰 바코드를 스캔할 경우 평점이 불인정되며, 실시간 평점 확인이 불가능합니다.
- 런치세션, 휴식시간, 일부 세션은 대한의사협회 연수교육 심사 기준에 따라 평점이 인정되지 않습니다.

3. 대한내과학회 분과전문의 평점

- 분과전문의 연수강좌: Education Workshop (최대 6점)
4/18(토) 08:00-11:20, 12:35-15:55, Rm. 300C
- [순환기]내과 분과전문의 (내과전문의번호 소지자)에 한합니다.
- 분과전문의 평점이 필요하신 경우 반드시 해당 회의장 입구에 설치된 출결등록 기기에 입실(세션시작)시 1회, 퇴실(세션종료)시 1회 명찰 바코드를 스캔해야 하며, 실 참석 시간에 따라 평점이 인정됩니다.

4. 내과전공의 외부학술회의 (학술대회) 평점

- 전공의에 한하여 인정되는 평점으로 개최기간 관계없이 총 2점 인정됩니다.
- 오전, 오후를 기준으로 각각 하나의 세션으로 간주하여 각 1점 인정됩니다.
[오전, 오후 모두 참석하였을 때 최대 2점 인정]

International Faculty



Ade Meidian Ambari
Universitas Indonesia -
National Cardiovascular
Center Harapan Kita
Indonesia



Adeeb H. Al-Quthami
SUNY Upstate Medical
University
USA



Aekarach Ariyachaipanich
Chulalongkorn University
Thailand



Alex Lee
The Chiness University of
Hong Kong
Hong Kong



Andrea M. Russo
Cooper Medical School of
Rowan University
USA



Bonnie Ky
University of Pennsylvania
School of Medicine
USA



Cynthia Taub
SUNY Upstate Medical
University
USA



Daichi Shimbo
Columbia University
USA



Derek J. Hausenloy
Duke-National University of
Singapore Medical School
Singapore



Eugene Yang
University of Washington School
of Medicine
USA




Federico M. Asch
MedStar Health and
Georgetown University
USA



Harlan M. Krumholz
Yale School of Medicine
USA



Hiroshi Akazawa
Kanazawa Medical University
Japan



Ippei Shimizu
National Cerebral and
Cardiovascular Center
Japan



Jae K. Oh
Mayo Clinic
USA



Jennifer A. Cowger
Henry Ford Health
USA



Junya Ako
Kitasato University
Japan



Kaoru Dohi
Mie University Graduate
School of Medicine
Japan



Kin-Lam Tsui
Pamela Youde Nethersole
Eastern Hospital
Hong Kong



Kwan Seung Lee
Mayo Clinic Arizona
USA



Lakshman Subrahmanyam
Dartmouth Hitchcock Medical
Center
USA



Leo Lopez
Stanford University
USA



Marat Fudim
Duke University
USA



Mayanna Lund
Health New Zealand
New Zealand

International Faculty



Melana Yuzefpolskaya
Columbia Presbyterian Irving
Medical Center
USA



Michael Ka Lam Wong
Cardiac Medical Unit,
Grantham Hospital
Hong Kong



Nuntakorn Thongtang
Mahidol University
Thailand



Pam R. Taub
UC San Diego Health
USA



**Pugazhendhi
Vijayaraman**
Geisinger Heart Institute
USA



Radityo Prakoso
National Cardiovascular
Centre Harapan Kita
Indonesia



Ramesh Babu Daggubati
West Virginia University
USA



Rodney Jimenez
St. Luke's Medical Center -
Global City
Philippines



Roxana Mehran
Icahn School of Medicine at
Mount Sinai
USA



Sanjay Tyagi
Apollo Hospital Group
India



**Smonporn Boonyaratavej
Songmuang**
King Chulalongkorn
Memorial Hospital
Thailand



Sootkeng Ma
Island Hospital Penang
Malaysia

International Faculty



Tiffany Chen
University of Washington
USA



Wei-Chun Huang
Pingtung Christian Hospital
National Sun Yat-sen
University
Taiwan



William Kong
The National University Heart
Centre Singapore
Singapore



Yuk Kong Lau
Lau Yuk Kong Clinic
Hong Kong

ACC ASIA 2026

Day 1 / 17(Fri.)

ENG Multimodal Imaging 1
(Joint Session with Korean Society of Echocardiography)

08:40-09:25 / Rm.205

Mitral Stenosis in the Modern Era: Rheumatic Legacy, Calcific Challenge, Percutaneous Promise

Chairperson(s) Smonporn Boonyaratavej Songmuang, Geu-Ru Hong
Panel Cynthia Taub, Jihoon Kim, Jae K. Oh

08:40 - 08:50 **Rheumatic Mitral Stenosis: The Complimentary Role of Echo and CT**
ACC

08:50 - 09:00 **Degenerative Mitral Annular Calcification: The Complimentary Role of Echo and CT**
Chi Young Shim / Yonsei Univ., Korea

09:00 - 09:10 **Multimodality Imaging Before and During Percutaneous Mitral Valve Intervention For MS**
Alex Lee / The Chiness Univ. of Hong Kong, Hong Kong

09:10 - 09:25 **Panel Discussion With Audience Question and Answer**

ENG Plenary 1

08:40-09:25 / Rm.300A

INOCA/ANOCA: An Emerging Global Issue

Chairperson(s) Harlan M. Krumholz, Myung Ho Jeong
Panel Kyung Il Park, Yuk Kong Lau, Kwan Seung Lee

08:30 - 08:40 **Case Presentation: Two Different Types of ANOCA**
Seong-Bong Wee / Ulsan Univ., Korea

08:40 - 08:50 **Clinical Outcomes and Approach to Management of INOCA/ANOCA**
Roxana Mehran / Icahn School of Medicine at Mount Sinai, USA

08:50 - 09:00 **Managing INOCA/ANOCA in Limited Resource Environments**
Rodney Jimenez / St. Luke's Medical Center-Global City, Philippines

09:00 - 09:15 **Panel Discussion With Audience Question and Answer**

1
Day

ACC ASIA 2026 TOGETHER
WITH
KSC SPRING CONFERENCE

17(Fri.)

ENG Special Topics 1

09:35-10:20 / Rm.202

Pediatric Cardiology: Prevention, Kawasaki Disease, and Lifelong Risk

Chairperson(s) Radityo Prakoso, I Seok Kang
Panel Eugene Yang, Su-Jin Park, Jae Yoon Na

- 09:35 - 09:45 **Prevention and Management of Long-term Cardiovascular Sequelae in Kawasaki Disease**
JinYoung Song / Sungkyunkwan Univ., Korea
- 09:45 - 09:55 **RVOT Stenting and PDA Stenting in Late Presenter Congenital Heart Disease**
Radityo Prakoso / National Cardiovascular Centre Harapan Kita, Indonesia
- 09:55 - 10:05 **Cardiovascular Risk in Grown-Up Congenital Heart Disease: Atherosclerosis and Beyond**
Ja Kyoung Yoon / Sungkyunkwan Univ., Korea
- 10:05 - 10:20 **Panel Discussion With Audience Question and Answer**

**ENG Multimodal Imaging 2
(Joint Session with Korean Society of Echocardiography)**

09:35-10:20 / Rm.205

Seeing Through the Thickness: The Power of Multimodality Imaging

Chairperson(s) Goo-Yeong Cho, Cynthia Taub
Panel Darae Kim, Seo Yeon Gwak, Jae K. Oh

- 09:35 - 09:45 **Multimodality Imaging in the Assessment of Thickened Myocardium**
Jiwon Seo / Yonsei Univ., Korea
- 09:45 - 09:55 **Multimodality Imaging in Amyloidosis**
William Kong / The National University Heart Centre Singapore, Singapore
- 09:55 - 10:05 **Multimodality Imaging in Athlete's Heart**
Jae Yeong Cho / Chonnam National Univ., Korea
- 10:05 - 10:20 **Panel Discussion With Audience Question and Answer**

ENG Cardiac Arrhythmias 1

09:35-10:20 / Rm.300A

Regional Differences in AFib Management

Chairperson(s) Sootkeng Ma, Dae Hyeok Kim
Panel Yae Min Park, Jun Beom Park, Andrea M. Russo

- 09:35 - 09:50 **Early Rhythm Control: The New Paradigm for AFib**
Andrea M. Russo / Cooper Medical School of Rowan University, USA
- 09:50 - 09:57 **Panel Discussion With Audience Question and Answer**
- 09:57 - 10:12 **Obesity: Lifestyle and Risk Factor Modification**
Ki Hong Lee / Chonnam National Univ., Korea
- 10:12 - 10:20 **Panel Discussion With Audience Question and Answer**

ENG Special Topics 2

10:30-11:15 / Rm.202

Women's Heart Disease: Hormones, Rhythm, and Risk

Chairperson(s) Roxana Mehran, Mi-Seung Shin
Panel Junya Ako, Bonnie Ky, Mi Na Kim

- 10:30 - 10:40 **Hormone Replacement Therapy and Heart Disease**
Pam R. Taub / UC San Diego Health, USA
- 10:40 - 10:50 **Anticoagulation and Afib in Asian Women**
Yae Min Park / Gachon Univ., Korea
- 10:50 - 11:00 **Rhythm Control Strategies in Women**
Andrea M. Russo / Cooper Medical School of Rowan University, USA
- 11:00 - 11:15 **Panel Discussion With Audience Question and Answer**

ENG **Heart Failure and Cardiomyopathies 1**
(Joint Society Session with Korean Society of Heart Failure)

10:30-11:15 / Rm.205

Heart Failure Management: Devices, AI, and Emerging Therapies

Chairperson(s) Jennifer A. Cowger, Hyun-Jai Cho
Panel Mayanna Lund, Kaoru Dohi, Aekarach Ariyachaipanich

- 10:30 - 10:40 **Emerging Devices in HFrEF Beyond CRT and LVAD**
Marat Fudim / Duke University, USA
- 10:40 - 10:45 **Panel Discussion With Audience Question and Answer**
- 10:45 - 10:55 **Using Artificial Intelligence to Improve Heart Failure Outcomes**
Jin Joo Park / Seoul National Univ., Korea
- 10:55 - 11:00 **Panel Discussion With Audience Question and Answer**
- 11:00 - 11:10 **Emerging Treatment Options for HFpEF**
Soo Yong Lee / Pusan National Univ., Korea
- 11:10 - 11:15 **Panel Discussion With Audience Question and Answer**

ENG **Valvular Diseases and Structural Interventions 1**

10:30-11:15 / Rm.300A

Valvular Interventions: Lessons from Challenging Cases

Chairperson(s) Rodney Jimenez, Dae-Hee Kim
Panel Sanjay Tyagi, In Sook Kang, Chan Soon Park

- 10:30 - 10:35 **Case Presentation: My Worst Case in TAVR/TAVI, What I Learned**
Jung-Min Ahn / Ulsan Univ., Korea
- 10:35 - 10:45 **Panel Discussion**
- 10:45 - 10:50 **Case Presentation: My Worst Case in Mitral TEER, What I Learned**
Eun Kyoung Kim / Sungkyunkwan Univ., Korea
- 10:50 - 11:00 **Panel Discussion**
- 11:00 - 11:05 **Case Presentation: My Worst Case in Tricuspid TEER, What I Learned**
Ramesh Babu Daggubati / West Virginia University, USA
- 11:05 - 11:15 **Panel Discussion**

ENG **Special Topics 3**

11:25-12:10 / Rm.202

Genomics and Genetics in Cardiovascular Disease: From Cardiomyopathy to Dyslipidemia

Chairperson(s) Seung Pyo Lee, Andrea M. Russo
Panel Mayanna Lund, Kyung-Hee Kim, Inki Moon

- 11:25 - 11:35 **Cardiomyopathy**
Lakshman Subrahmanyam / Dartmouth Hitchcock Medical Center, USA
- 11:35 - 11:45 **Aortopathy**
Adeeb H. Al-Quthami / SUNY Upstate Medical University, USA
- 11:45 - 11:55 **Genetics in Dyslipidemia**
Sang-Hak Lee / Yonsei Univ., Korea
- 11:55 - 12:10 **Panel Discussion With Audience Question and Answer**

ENG **Heart Failure and Cardiomyopathies 2**
(Joint Society Session with Korean Society of Heart Failure)

11:25-12:10 / Rm.205

Obesity, Inflammation, and Heart Failure: Treating the Whole Disease

Chairperson(s) Byung Su Yoo, Young Min Cho
Panel Jennifer A. Cowger, Chan Joo Lee, Cynthia Taub

- 11:25 - 11:35 **Obesity and Heart Failure: Understanding Cardiometabolism and Inflammation**
Jong-Chan Youn / Catholic Univ., Korea
- 11:35 - 11:40 **Panel Discussion With Audience Question and Answer**
- 11:40 - 11:50 **Gut Inflammation and Heart Failure**
Melana Yuzefpolskaya / Columbia Presbyterian Irving Medical Center, USA
- 11:50 - 11:55 **Panel Discussion With Audience Question and Answer**
- 11:55 - 12:05 **The Role of GLP1 in HFrEF and HFpEF**
Dong-Hyuk Cho / Korea Univ., Korea
- 12:05 - 12:10 **Panel Discussion With Audience Question and Answer**

ENG Valvular Diseases and Structural Interventions 2 11:25-12:10 / Rm.300A**Updates in the Guidelines: What to Know**

Chairperson(s) Ramesh Babu Daggubati, June Hong Kim
Panel Jae hyun Lim, Sanjay Tyagi, ACC

- 11:25 - 11:35 **Mixed Moderate AS and AR: To Intervene or to Wait**
Sung Ji Park / Sungkyunkwan Univ., Korea
- 11:35 - 11:45 **Secondary MR: To Intervene or to Wait**
Kwan Seung Lee / Mayo Clinic Arizona, USA
- 11:45 - 11:55 **Severe Secondary TR: To Intervene or to Wait**
Jun-Bean Park / Seoul National Univ., Korea
- 11:55 - 12:10 **Panel Discussion With Audience Question and Answer**

ENG Opening Ceremony 13:10-13:20 / Rm.300B

Presenters Seok-Min Kang, Kwan Seung Lee, Roxana Mehran

ENG Coronary Interventions and Ischemic Heart Diseases 1 14:15-15:00 / Rm.202**AI in Action: Transforming Coronary Intervention from Planning to Precision**

Chairperson(s) Sanjay Tyagi, Jung-Sun Kim
Panel Yuk Kong Lau, Doo Sun Sim, In Ho Yang

- 14:15 - 14:25 **Beyond the FLASH Trial: Non-Intracoronary Based Imaging Artificial Intelligence for PCI Planning**
Yong Cheol Kim / Yonsei Univ., Korea
- 14:25 - 14:30 **Panel Discussion With Audience Question and Answer**
- 14:30 - 14:40 **Artificial Intelligence in AMI ECG: Detecting Occlusion beyond STEMI**
Kwan Seung Lee / Mayo Clinic Arizona, USA
- 14:40 - 14:45 **Panel Discussion With Audience Question and Answer**
- 14:45 - 14:55 **The Role of Artificial Intelligence in Intracoronary Imaging**
Jin Won Kim / Korea Univ., Korea
- 14:55 - 15:00 **Panel Discussion With Audience Question and Answer**

ENG Cardiovascular Disease Prevention 1 14:15-15:00 / Rm.205
(Joint Session with Korean Society of Lipid and Atherosclerosis)**2025 Cholesterol Guidelines: Integration and Application in Asia**

Chairperson(s) Ade Meidian Ambari, Sang-Hyun Kim
Panel Hyun-Jin Kim, Hack-Lyoung Kim

- 14:15 - 14:25 **Overview of 2025 ACC/AHA Blood Cholesterol Guideline**
Eugene Yang / University of Washington School of Medicine, USA
- 14:25 - 14:30 **Discussion**
- 14:30 - 14:40 **Integration of the ACC/AHA Guideline Into Korean Dyslipidemia Management: KSoLA Perspective**
Youngwoo Jang / Gachon Univ., Korea
- 14:40 - 14:45 **Discussion**
- 14:45 - 14:55 **Adoption of Lipid Guidelines in Asia: Challenges and Opportunities**
Minkwan Kim / Yonsei Univ, Korea
- 14:55 - 15:00 **Discussion**

ENG Heart Failure and Cardiomyopathies 3 14:15-15:00 / Rm.300A**Complex Cardiomyopathies: Diagnostic Innovations and Therapeutic Advances**

Chairperson(s) Kaoru Dohi, Byung-Hee Oh
Panel Sunki Lee, In-Chang Hwang, Aekarach Ariyachaipanich

- 14:15 - 14:25 **Amyloidosis**
Darae Kim / Sungkyunkwan Univ., Korea
- 14:25 - 14:30 **Panel Discussion With Audience Question and Answer**
- 14:30 - 14:40 **Sarcoidosis**
Jennifer A. Cowger / Michigan State University, USA
- 14:40 - 14:45 **Panel Discussion With Audience Question and Answer**
- 14:45 - 14:55 **Hypertrophic Cardiomyopathy**
Hyung-Kwan Kim / Seoul National Univ., Korea
- 14:55 - 15:00 **Panel Discussion With Audience Question and Answer**

ENG Special Topics 4

15:10-15:55 / Rm.202

Cardio-Oncology: Bridging Cancer and Cardiovascular Care

Chairperson(s) Bonnie Ky, Il Suk Sohn
Panel Mayanna Lund, Kaoru Dohi, Jeong-Eun Yi

- 15:10 - 15:20 **Cardiovascular Effects of Common Cancer Therapies**
Bonnie Ky / University of Pennsylvania School of Medicine, USA
- 15:20 - 15:30 **Evidence Based Strategies for Risk Prediction**
Yun Gyoo Lee / Sungkyunkwan Univ., Korea
- 15:30 - 15:40 **Importance of Modifiable Cardiovascular Risk Factors in Our Patients With Cancer**
Hyukjin Park / Chonnam National Univ., Korea
- 15:40 - 15:55 **Panel Discussion With Audience Question and Answer**

ENG Cardiovascular Disease Prevention 2

(Joint Session with Korean Society of Lipid and Atherosclerosis)

15:10-15:55 / Rm.205

Beyond Statins: Novel Therapies For Dyslipidemia and Cardiovascular Prevention

Chairperson(s) Sung Rae Kim, Eugene Yang
Panel Jun-Hee Lee, Seonghoon Choi, Dae Young Cheon

- 15:10 - 15:20 **PCSK9 Inhibition, From Monoclonal Antibodies to Small Molecules**
Kwon Oh Sung / Catholic Univ., Korea
- 15:20 - 15:25 **Discussion**
- 15:25 - 15:35 **Bempedoic Acid, Expanding Options for Statin-Intolerant Patients**
Eugene Yang / University of Washington School of Medicine, USA
- 15:35 - 15:40 **Discussion**
- 15:40 - 15:50 **Next-Generation Therapies Targeting Lipoprotein(a) and Apolipoprotein B- The Promise of ASO and siRNA Platforms**
Jin Wi / Gachon Univ, Korea
- 15:50 - 15:55 **Discussion**

ENG Valvular Diseases and Structural Interventions 3

15:10-15:55 / Rm.300A

Asymptomatic Severe Valve Disease: Evidence and Decision-Making

Chairperson(s) Geu-Ru Hong, Roxana Mehran
Panel Ramesh Babu Daggubati, Yeonyee E. Yoon, Jung Hyun Choi

- 15:10 - 15:15 **Case Presentation: Asymptomatic Primary MR**
Ye Chan Kim / Sungkyunkwan Univ., Korea
- 15:15 - 15:25 **Asymptomatic MR: A Dive into Evidence**
Seung Pyo Lee / Seoul National Univ., Korea
- 15:25 - 15:30 **Case Presentation: Asymptomatic Severe Aortic Stenosis**
Sang Hyun Kim / Catholic Univ., Korea
- 15:30 - 15:40 **Asymptomatic AS: A Dive into Evidence**
Ramesh Babu Daggubati / West Virginia University, USA
- 15:40 - 15:55 **Panel Discussion With Audience Question and Answer**

ENG Coronary Interventions and Ischemic Heart Diseases 2

(Joint Session with Korean Society of Interventional Cardiology)

16:05-16:50 / Rm.205

Breaking Barriers in Complex High-Risk PCI: Innovations and Strategies

Chairperson(s) Sanjay Tyagi, Youngkeun Ahn
Panel Joo-Yong Hahn, Jung-Sun Kim, Kwan Seung Lee

- 16:05 - 16:15 **Advances in Managing Calcified, Balloon Non-crossable Lesions**
Kwan Seung Lee / Mayo Clinic Arizona, USA
- 16:15 - 16:20 **Panel Discussion With Audience Question and Answer**
- 16:20 - 16:30 **Hybrid Bifurcation Approaches With Drug-Coated Balloons**
Ae-Young Her / Kangwon National Univ., Korea
- 16:30 - 16:35 **Panel Discussion With Audience Question and Answer**
- 16:35 - 16:45 **Mechanical Circulatory Support in High-Risk PCI**
Ramesh Babu Daggubati / West Virginia University, USA
- 16:45 - 16:50 **Panel Discussion With Audience Question and Answer**

ENG Plenary 2

16:05-16:50 / Rm.300A

Leveraging AI in EMR and Beyond

Chairperson(s) Eugene Yang, Yong-Jin Kim
Panel Cynthia Taub, William Kong, Jun Hwan Cho

- 16:05 - 16:20 **US Perspective: How to Leverage AI in the EMR Environment**
 Harlan M. Krumholz / Yale School of Medicine, USA
- 16:20 - 16:35 **Korean Perspective: How to Leverage AI in the EMR Environment**
 Seng Chan You / Yonsei Univ., Korea
- 16:35 - 16:50 **Panel Discussion With Audience Question and Answer**

**ENG Coronary Interventions and Ischemic Heart Diseases 3
(Joint Session with Korean Society of Interventional Cardiology)**

17:00-17:45 / Rm.205

Inside the Vessel: Advanced Imaging and Physiology For Complex PCI

Chairperson(s) Bon-Kwon Koo, Kin-Lam Tsui
Panel Roxana Mehran, Hyuck-Jun Yoon, Jung-Min Ahn

- 17:00 - 17:10 **Understanding Intracoronary Physiology Discrepancies in Hyperemic vs Non-Hyperemic Modalities**
 Janghoon Lee / Kyungpook National Univ., Korea
- 17:10 - 17:15 **Panel Discussion With Audience Question and Answer**
- 17:15 - 17:25 **Beyond RENOVATE-COMPLEX PCI: Future Directions for Intracoronary Imaging**
 Joo Myung Lee / Sungkyunkwan Univ., Korea
- 17:25 - 17:30 **Panel Discussion With Audience Question and Answer**
- 17:30 - 17:40 **How Will CABG Compare With Standardized Best Practice Contemporary Multi-vessel PCI**
 Kwan Seung Lee / Mayo Clinic Arizona, USA
- 17:40 - 17:45 **Panel Discussion With Audience Question and Answer**

ENG FIT Jeopardy: The Classic Game Show With a FIT Twist!

17:00-17:45 / Rm.300A

Host Eugene Yang
Judge Yuk Kong Lau

17:00 - 17:45 **Teams: South Korea, Philippines, China and Singapore**

KSC SPRING CONFERENCE**Day 1 / 17(Fri.)****Basic Research 1**

08:40-10:10 / Rm.102

유전자 편집 기술의 원리부터 심혈관질환 임상 적용까지

Chairperson(s) 정진욱, 민필기
Panel 김영국, 김종호, 나지훈, 양한모, 허경선

Learning Objective

유전자 편집 기술에 대한 기초부터 임상 적용까지 소개하는 세션입니다.

- 08:40 - 08:58 **Principles of Gene Editing: From CRISPR-Cas9 to Next-Generation Editing Tools**
 김경미 / 서울대학교
- 08:58 - 09:16 **DNA Editing**
 김희권 / 성균관대학교
- 09:16 - 09:34 **RNA Editing**
 김영광 / 가톨릭의대
- 09:34 - 09:52 **Clinical Application of Gene Editing**
 김정훈 / 서울의대
- 09:52 - 10:10 **Discussion**

Myocardial Infarction 1

08:40-10:10 / Rm.104

심근경색증 진단하기 (증례를 중심으로)

Chairperson(s) 황진용, 홍영준
Panel 박종필, 윤창환, 이상엽, 임홍석, 최웅길

Learning Objective

1. AI 시대, 심근경색증 환자에서 AI 심전도의 효용과 안전성에 대해 알아봅니다.
2. 심근경색증진단에 있어서 심전도, 트로포닌 검사 및 비침습적검사를 해석하고 활용하는 방법에 대해 알아봅니다.
3. 심근경색증 및 이와 유사한 질환들을 감별진단하는 노하우를 터득합니다.

- 08:40 - 08:55 **AI 심전도 제대로 활용하기**
조경훈 / 전남의대
- 08:55 - 09:10 **고감도트로포닌검사 어떻게 해석하고 적용할 것인가?**
원호연 / 중앙의대
- 09:10 - 09:25 **심근경색증의 비침습적 영상학적 검사 (Cardiac CT & MRI): 역할과 활용**
신상훈 / 이화의대
- 09:25 - 09:40 **심근경색증인가요? 네, 맞습니다.**
강민규 / 경상의대
- 09:40 - 09:55 **심근경색증이 아닌가요? 네, 아닙니다.**
김홍년 / 경북의대
- 09:55 - 10:10 **Discussion**

ENG Hypertension

08:40-10:10 / Rm.105

New Era of Out-of-Office BP Monitoring: Guidelines, Evidence, and Technology

Chairperson(s) Jinho Shin, Kwang-il Kim
Panel Sung Ha Park, Jeong-Hun Shin, Eun Mi Lee, Hae-Young Lee

Learning Objective

1. To understand the technical principles of Cuffless BP monitoring and the current level of clinical validation.
2. To distinguish the expected clinical utility and limitations based on existing research findings.
3. To explain the role of cuffless blood pressure monitoring within current guidelines and outline future research directions.

- 08:40 - 08:55 **Cuffless Blood Pressure Monitoring: Validation Status, Accuracy, and Reproducibility**
Min Gyu Kong / Soonchunhyang Univ., Korea
- 08:55 - 09:10 **White Coat and Masked Hypertension: What Can Cuffless BP Monitoring Add?**
Hyung Joon Joo / Korea Univ., Korea
- 09:10 - 09:25 **Nocturnal Hypertension and BP Dipping: Measuring the Unmeasurable**
Jieun Lee / Korea Univ., Korea
- 09:25 - 09:45 **Cuffless BP Devices: Hype, Hope, and Hard Truths**
Daichi Shimbo / Columbia University, USA
- 09:45 - 10:10 **Discussion**

KSHF 1

08:40-10:10 / Rm.203

Modern Drug Therapy for Heart Failure in Real Clinical Practice

Chairperson(s) 홍석근, 정육진

Panel 김민석, 이찬주, 이희정, 한성우

Learning Objective

1. 최신 임상근거가 계속 확장되고 있는 새로운 심부전 약물을 증례를 통하여 Problem Solving하고 새로운 Evidence를 공부해 보는 세션입니다.
2. 주요 임상시험 근거를 바탕으로 각 치료 전략이 어떤 심부전 표현형과 환자군에서 가장 큰 임상적 이점을 가질 수 있는지를 해석할 수 있습니다.
3. 심부전 약물치료의 패러다임의 변화와 흐름을 이해할 수 있습니다.

- 08:40 - 08:55 **ARNI in HF mrEF and HFpEF: Expanding the Therapeutic Horizon**
[박출물 경도감소 및 보존 심부전에서 ARNI의 효과와 전망]
조현재 / 서울의대
- 08:55 - 09:10 **Balanced Use of SGLT2 Inhibitor with Diuretics in HF**
[심부전 치료에서 SGLT2 inhibitor를 이뇨제와 적절히 사용하기]
전경현 / 연세의대
- 09:10 - 09:25 **(ENG) Practical Approaches to GDMT Optimization in Challenging Clinical Settings**
[복잡한 임상상황에서의 GDMT 최적화 전략]
Aekarach Ariyachaipanich / Chulalongkorn Univ., Thailand
- 09:25 - 09:40 **GLP-1 Receptor Agonist in Heart Failure: A New Weapon Against a Major Enemy**
[심부전 환자의 비만 치료: 임상적용 실제]
박진주 / 서울의대
- 09:40 - 09:55 **Mavacamten in Obstructive HCM: Redefining Targeted Therapy**
[폐색성 비후성심근증에서 마바캄텐 치료의 다양한 경험]
손정우 / 연세원주의대
- 09:55 - 10:10 **Discussion**

Cardiometabolic Syndrome 1

08:40-10:10 / Rm.300B

Deconstructing the "Fatty" CKM: Adiposity and Inflammation

Chairperson(s) 한승환, 김병진

Panel 박재형, 서재빈, 우종신, 천대영

Learning Objective

1. 이소성 지방의 국소 병태생리: PVAT, EAT, 간지방이 염증신호와 기계적 압박으로 죽상경화증, 심부전, 지방간, 인슐린저항성을 유발하는 기전을 이해할 수 있습니다.
2. 장기별 손상 기전 규명: 각 장기의 해부학적 위치에 따라 지방이 유발하는 손상 기전이 염증성 신호[Chemical] 인지, 혹은 '물리적 압박[Mechanical] 인지에 대해 학습합니다.
3. 이소성 지방의 재정의와 CKM 병태생리: 단순 BMI를 넘어 심장, 혈관, 간의 지방 축적이 CKM 질환을 유발하는 주요 기전일 수 있음을 이해할 수 있습니다.

- 08:40 - 08:55 **Obesity-Related Hypertension: Cardiometabolic Insights**
조상호 / 한림의대
- 08:55 - 09:10 **Central Adiposity or Hypertension: Which Drives HFpEF?**
최정천 / 부산의대
- 09:10 - 09:25 **Epicardial Adipose Tissue (EAT): Mechanical Constraint or Paracrine Toxicity?**
서미혜 / 순천향의대
- 09:25 - 09:40 **Perivascular Adipose Tissue (PVAT): The "Outside-In" Signaling in Atherosclerosis**
박훈준 / 가톨릭의대
- 09:40 - 09:55 **Metabolic Engine of CKM: Insulin Resistance and Liver Fat**
박세은 / 성균관대의대
- 09:55 - 10:10 **Discussion**

Interesting ECG08:40-10:10 / Rm.300C

Chairperson(s)허준, 온영근
Panel김예지, 박윤정, 신동금, 양소영, 정주희

Learning Objective

1. 서맥·빈맥·심박동기·소아 ECG를 포함한 다양한 부정맥 심전도를 체계적으로 해석할 수 있는 능력을 습득합니다.
2. Narrow QRS 및 Wide QRS 빈맥 감별 시 핵심 포인트와 혼란 오류를 케이스 기반으로 이해합니다.
3. 웨어러블 및 AI 기반 심전도 판독의 임상적 활용 범위와 진단적 한계를 파악하여 실제 진료에 적용합니다.

08:40 - 08:55	What Are the Key ECG Findings in Bradycardia and Pacemaker Rhythms? 김문현 / 이화의대
08:55 - 09:10	Practical Differentiation of Narrow QRS Tachycardia: What Matters Most? 이영신 / 경희의대
09:10 - 09:25	Wide QRS Tachycardia: Is It VT or Not? 정민수 / 계명의대
09:25 - 09:40	What Are the Key ECG Features in Pediatric and Congenital Heart Disease? 차누리 / 연세의대
09:40 - 09:55	ECG from Wearables & AI-Driven ECG Interpretation: What Should Clinicians Know? 백용수 / 인하의대
09:55 - 10:10	Discussion

ENG Basic Research 210:30-12:00 / Rm.102

From Bedside to Bench: Patient-Derived Samples in Cardiovascular Research

Chairperson(s)Jin Han, Hun-Jun Park
PanelHae Young Yang, Chang-Myung Oh, Sung Woo Cho, Hyung Joon Joo

Learning Objective

This session introduces cardiovascular translational research that can be conducted using patient-derived samples (e.g., blood, tissue).

10:30 - 10:48	Targeting Fibrosis in Cardiovascular-metabolic Diseases Ippei Shimizu / National Cerebral and Cardiovascular Center, Japan
10:48 - 11:06	High-definition Spatial Mapping of the Peri-fibrotic Remodeling Front in End-stage Ischemic Cardiomyopathy Kwon Joong Na / Seoul National Univ., Korea
11:06 - 11:24	Disease Modeling by Using Patient Specific iPSC-derived Cell Derek J. Hausenloy / Duke-National University of Singapore Medical School, Singapore
11:24 - 11:42	Patient-Derived Aortic Valve Omics for Mechanistic Studies in Aortic Stenosis Sahmin Lee / Ulsan Univ., Korea
11:42 - 12:00	Discussion

Insurance Issues10:30-12:00 / Rm.104

심장분야 의료기기 및 혁신AI기술의 국산화와 과제

Chairperson(s)구본권, 서준
Panel김성철, 김준영, 오일영, 유정민, 이승률

10:30 - 10:45	심장 진료의 새로운 전환: 진단 보조 AI의 임상 적용과 급여의 현실 백용수 / 인하의대
10:45 - 11:00	디지털 헬스케어의 시장 진입과 규제 (혁신의료기술 업계의 고충) 심은보 / AI Medic
11:00 - 11:15	Discussion
11:15 - 11:30	국산의료기기 개발 경험과 과제 천민구 / 부산의대
11:30 - 11:45	국산 심혈관 치료재료 개발 현실과 애로사항 (스텐트, 카테터 등 의료기기 제조 기술 중심으로) 김우진 / KITECH
11:45 - 12:00	Discussion

Pulmonary Hypertension

10:30-12:00 / Rm.105

Current Therapeutic Approaches in Pulmonary Hypertension

Chairperson(s) 정육진, 김계훈
Panel 국형돈, 나진오, 이원재, 정세웅

Learning Objective

1. 폐고혈압의 분류를 이해합니다.
2. 폐고혈압 각 군의 특성과 진단, 치료에 대해 이해합니다.

10:30 - 10:45	Pulmonary Arterial Hypertension (PAH) 이상은 / 이화여대
10:45 - 11:00	Pulmonary Hypertension in Left Heart Disease 최진오 / 성균관대의대
11:00 - 11:15	Pulmonary Hypertension in Chronic Lung Disease 장항제 / 인제대의대
11:15 - 11:30	Chronic Pulmonary Thromboembolism Pulmonary Hypertension (CTEPH) 안철민 / 연세의대
11:30 - 11:45	WHO Group 5 Pulmonary Hypertension 백승민 / 서울의대
11:45 - 12:00	Discussion

Cardiac Pathology

10:30-12:00 / Rm.203

Tissue Based Approach: Integrated Patho-cardiology Strategies for Immune Checkpoint Inhibitor Myocarditis and Radiation Induced Heart Disease

Chairperson(s) 이창하, 정우백
Panel 김형섭, 서정욱, 윤현주, 조정선, 황희정

Learning Objective

1. 면역항암제 투여 후, 발생하는 심근염의 병리학적 기전을 histopathology 및 면역염색(IHC) 이미지를 통해 직관적으로 이해합니다.
2. ICI myocarditis가 의심되는 임상 상황에서 심근 생검(endomyocardial biopsy)의 전략적 접근 방법을 실제 임상 사례를 통해 학습합니다.
3. 방사선 조사 선량 및 치료 기법의 발전에 따라 변화하고 있는 방사선 유발 심장질환(Radiation-Induced Heart Disease)의 발생 양상과 임상적 스펙트럼을 이해합니다.
4. 심장에 방사선치료가 시행되었을 때 발생하는 조직학적 손상과 병리 형태학적 변화(histomorphology)를 실제 심장 조직 이미지를 통해 직관적으로 이해하여 임상에서 관찰되는 심혈관 합병증과의 연관성을 파악합니다.

10:30 - 10:50	Pathological Features of ICI Myocarditis 김정선 / 성균관대의대
10:50 - 11:10	Biopsy-guided Therapy for ICI Myocarditis (Clinical Impact and Outcomes) 정미향 / 가톨릭의대
11:10 - 11:30	Evolving Clinical Landscape of Radiation-Induced Heart Disease in Modern Thoracic Radiotherapy 윤홍인 / 연세의대
11:30 - 11:50	Pathological Insights of Radiation-Induced Heart Disease 김은나 / 서울의대
11:50 - 12:00	Discussion

Cardiometabolic Syndrome 2

10:30-12:00 / Rm.300B

RNA Revolution: Silencing the Drivers of CKM Syndrome

Chairperson(s) 유승기, 김원

Panel 김성은, 김장영, 남궁준, 문정근, 홍순준

Learning Objective

1. 최근 새로운 치료 전략으로 대두되고 있는 RNA 기반 치료의 작용 기전과 임상적 의미를 이해합니다. siRNA, ASO 등 RNA therapeutics가 유전자 발현을 조절하는 분자생물학적 기전과 이를 통해 이상지질혈증, 고혈압, 심부전 등 CKM 증후군을 구성하는 각 임상질환의 핵심 병태생리에 어떻게 개입하는지를 이해합니다.
2. 이상지질혈증, 고혈압, 심부전 영역에서 RNA therapeutics의 임상적 근거와 치료 전략을 비교·평가합니다.
3. RNA 치료의 한계, 안전성, 실제 임상 적용 시 고려사항을 통합적으로 인식합니다.

10:30 - 10:50	Dawn of Gene Silencing: Mechanism and Potential of RNA Therapeutics in CKM Syndrome 위진 / 가천의대
10:50 - 11:05	Navigating the Maze: Challenges and Breakthroughs of RNA Therapies in HF 김경희 / 인천세종병원
11:05 - 11:25	Shifting the Paradigm in Lipid Management with RNA Therapeutics 김남훈 / 고려의대
11:25 - 11:40	Beyond Conventional Pills: RNA Therapeutics as the Next Frontier in Hypertension Control 안효석 / 가톨릭의대
11:40 - 12:00	Discussion

KHRS1-AF

10:30-12:00 / Rm.300C

Atrial Fibrillation: State-of-the-Art 2026

Chairperson(s) 곽충환, 이명용

Panel 김윤기, 손장원, 안민수, 장성원, 조영진

Learning Objective

1. AF ablation 후 장기 항응고 치료 지속의 필요성에 대한 최신 근거와 변화된 접근을 이해합니다.
2. Device-detected AF 환자에서 항응고 치료의 필요성과 시기를 결정하는 최신 임상 근거를 이해하고 적용할 수 있습니다.
3. PFA를 이용한 AF 절제술에서 PVI 이외 영역에 대한 시술 전략의 근거와 향후 방향을 논의합니다.
4. HFpEF와 AF가 동반된 환자에서 최적의 치료 전략을 이해하고, 약물 치료와 조기 리듬 조절의 역할을 비교해 봅니다.
5. 좌심방이 폐색술의 현재 역할과 임상 근거를 이해하고, 향후 발전 방향을 파악할 수 있도록 합니다.

10:30 - 10:45	Stroke Prevention After AF Ablation: How Are Long-Term Anticoagulation Strategies Changing? 김대훈 / 연세의대
10:45 - 11:00	When and in Whom Should Anticoagulation Be Initiated for Device-Detected Atrial Fibrillation? 윤남식 / 전남의대
11:00 - 11:15	How Can Pulsed Field Ablation Redefine AF Ablation Strategies Beyond Pulmonary Vein Isolation? 박형섭 / 계명의대
11:15 - 11:30	How Should HFpEF With AF Be Optimally Managed: Medical Therapy or Early Rhythm Control? 서지원 / 연세의대
11:30 - 11:45	What Is the Role of Left Atrial Appendage Closure in 2026: Current Evidence and Future Directions? 권순일 / 차의대
11:45 - 12:00	Discussion

Scientific Session [Chong Kun Dang]

12:20-13:00 / Rm.102

Evolution of Cardiovascular Care: Redefining Strategies for Hypertension and Heart Failure

Chairperson(s) 최정현, 박형섭

12:20 - 12:40 **Paradigm Shift in HTN Treatment: Role of Low-dose Dual Combination**
한정규 / 서울의대12:40 - 13:00 **Optimizing Heart Failure Treatment: Revisiting Carvedilol and Expanding with Vericiguat**
김봉준 / 고신의대

Scientific Session [Hanmi]

12:20-13:00 / Rm.105

Early Combination Therapy: A Paradigm Shift in CVD Treatment

Chairperson(s) 김광일, 김병국

12:20 - 12:40 **Ultra-Low-Dose Triple FDC in Hypertension: A New Initial Treatment Paradigm and the Patients Who Benefit**
김대희 / 울산의대12:40 - 13:00 **Beyond The Statin; Start Early, Switch Now**
권오성 / 가톨릭의대

Scientific Session [Novartis]

12:20-13:00 / Rm.203

Beyond LDL-C Reduction: Consistent Control

Chairperson(s) 채인호, 김상현

12:20 - 12:35 **Bridging the Gap in LDL-C Control with the Long-Sustained Efficacy of Inclisiran**
최기홍 / 성균관대의대12:35 - 12:50 **Redefining LDL-C Control through Minimizing LDL-C Variability with Inclisiran**
차정준 / 고려의대12:50 - 13:00 **Discussion**

Scientific Session [Samjin]

12:20-13:00 / Rm.205

Contemporary Approaches to Managing Pediatric Pulmonary Arterial Hypertension

Chairperson(s) 강이석

12:20 - 12:40 **From Guidelines to Patient Care: Practical Approaches to Managing Eisenmenger Syndrome**
정현 / 부천세종병원12:40 - 13:00 **Long-term Management of Pediatric Pulmonary Arterial Hypertension**
정세용 / 연세의대

Scientific Session [Organon]

12:20-13:00 / Rm.300A

Redefining Lipid Control with Atorvastatin Plus Ezetimibe for Early and Optimal LDL-C Reduction

Chairperson(s) 전국진, 남창욱

12:20 - 12:40 **Start Early: Upfront Lipid-Lowering Combination Therapy for Early Achievement of LDL-C Treatment Goals**
위진 / 가천의대12:40 - 13:00 **Start Strong: Elevating LDL-C Management in ASCVD with High-Dose Atorvastatin Plus Ezetimibe**
서석민 / 가톨릭의대

Scientific Session [Amgen]

12:20-13:00 / Rm.300B

The Evolving Role of Evolocumab in ACS: Optimizing Lipid Management and Cardiovascular Outcomes

Chairperson(s) 구분권, 정진욱
Panel 조형원, 최익준12:20 - 12:35 **Bridging the Gap in Lipid Management: Between Guideline and Real-World Practice**
조경훈 / 전남의대12:35 - 12:50 **Evolocumab in ACS: Early Initiation for Long-Term Cardiovascular Benefit**
김용철 / 연세의대12:50 - 13:00 **Discussion**

Scientific Session [Boryung]

12:20-13:00 / Rm.300C

Comprehensive Cardiovascular Disease Management

Chairperson(s)	강석민, 유병수
12:20 - 12:40	Optimal Approach for HMOD Management with Fimasartan Combination Theraphy 신성희 / 인하의대
12:40 - 13:00	New Treatment Option for Patients with Hypertension and Dyslipidemia 홍승표 / 대구가톨릭의대

ENG Opening Ceremony

13:10-13:20 / Rm.300B

Presenters	Seok-Min Kang, Kwan Seung Lee, Roxana Mehran
------------	--

ENG Suh, Soon Kyu Memorial Lecture

13:20-14:00 / Rm.300B

Chairperson(s)	Youngkeun Ahn, Seok-Min Kang
13:20 - 14:00	Cardiovascular Medicine in the Age of Intelligent Systems: From Data to Trust Harlan M. Krumholz / Yale School of Medicine, USA

Adult Congenital Heart Disease 1

14:15-15:45 / Rm.102

Pulmonary Arterial Hypertension in Adult Congenital Heart Disease: From Pathophysiology to Management

Chairperson(s)	허준, 은영민
Panel	김지나, 박재형, 조화진, 최광호, 허란
Learning Objective 1. ACHD에서 발생하는 폐동맥고혈압을 이해합니다. 2. 폐동맥고혈압 환자에서 적용가능한 최신 약제 및 수술적 치료를 압니다. 3. 경계성 PAH 를 이해하고 치료에 대해 토의합니다.	
14:15 - 14:30	Pathophysiology of PAH(Pulmonary Arterial Hypertension) in ACHD 정세용 / 연세의대
14:30 - 14:45	New Emerging Therapeutic Agents for PAH in ACHD 윤현주 / 전남의대
14:45 - 15:00	Borderline PAH in ACHD, Definition and Management 백재숙 / 울산의대
15:00 - 15:15	Imaging of PAH in ACHD 이상현 / 부산의대
15:15 - 15:30	Surgical Management of PAH in ACHD 최은석 / 울산의대
15:30 - 15:45	Discussion

Myocardial Infarction 2

14:15-15:45 / Rm.104

심근경색증 치료하기 (최신연구를 중심으로)

Chairperson(s) 정영호, 김원
 Panel 김우현, 김웅, 박성준, 한주용, 하정호

Learning Objective

1. 최근 발표된 항혈소판제나 베타차단제 등의 최신 연구 결과를 확인하고 연구의 의의를 알아봅니다.
2. 최근 개정된 고지혈증진료지침을 확인하고 새로운 약제를 이용한 지질강화전략을 알아봅니다.
3. 중재시술 분야에서 최근에 발표된 연구들을 정리하고 임상에 어떻게 적용할 것인지를 알아봅니다.

- 14:15 - 14:30 **복잡한 항혈소판제제 최신연구 한번에 정리하기**
 김송이 / 제주의대
- 14:30 - 14:45 **강화된 지질치료전략 어떻게 적용할 것인가?**
 이승준 / 연세의대
- 14:45 - 15:00 **베타차단제 누구에게 쓰고 언제 중단할 것인가?**
 박종일 / 영남의대
- 15:00 - 15:15 **다혈관질환자의 관상동맥 중재시술 어떻게 할 것인가?**
 박상호 / 순천향의대
- 15:15 - 15:30 **심인성쇼크 환자의 기계적 순환장치: 누구에게, 어떤 것을, 언제 시행할 것인가?**
 이수용 / 부산의대
- 15:30 - 15:45 **Discussion**

Women Heart Disease

14:15-15:45 / Rm.105

Sex-Based Differences in Emerging Cardiovascular Risk Factors

Chairperson(s) 김기식, 신미승
 Panel 김수진, 박용현, 조인정, 황경국

Learning Objective

1. 심혈관 질환 위험인자의 성차를 이해하고, 기존의 전통적 위험인자 외에 새롭게 부각되는 심대사·정신건강·사회적 요인이 여성 심혈관 질환 발생과 예후에 미치는 영향을 설명할 수 있습니다.
2. 임신·출산, 암 치료, 정신건강 문제 등 여성의 생애주기 및 특수 임상 상황에서 나타나는 심혈관 위험을 인지하고, 성별을 고려한 위험 평가와 추적 관리 전략의 필요성을 이해합니다.

- 14:15 - 14:30 **Cardiometabolic Health**
 조상호 / 한림의대
- 14:30 - 14:45 **Updates in Cardio-obstetrics**
 임경희 / 동아의대
- 14:45 - 15:00 **Social Determinants of Health in Cardiovascular Disease**
 김혜미 / 중앙의대
- 15:00 - 15:15 **Mental Health and Cardiovascular Health**
 조은주 / 가톨릭의대
- 15:15 - 15:30 **Cardio-oncology in Women**
 진정연 / 을지의대
- 15:30 - 15:45 **Discussion**

Cardiovascular Imaging

14:15-15:45 / Rm.203

From Cancer Therapy to Cardiac Injury: Clinical and Imaging Perspectives on Cardiotoxicity, Including ICI-Related Myocarditis

Chairperson(s) Jae K. Oh, 김대희
 Panel 문정근, 소문승, 손지희, 팽진철

Learning Objective

1. 암치료 분야의 빠른 발전으로 새로운 항암치료제들이 빠른 속도로 등장하고 있다. 이러한 최신 항암치료가 심혈관계에 미치는 영향을 이해하고, 고위험 환자를 식별할 수 있습니다.
2. Immune checkpoint inhibitor로 인한 심근염의 다양한 임상 시나리오를 이해하고 진단 알고리즘을 이해합니다.
3. 심초음파에 대하여 심장 MRI와 핵의학 영상의 심독성 평가 및 ICI 관련 심근염 진단에서의 역할을 이해하고 적절한 영상기법을 선택 및 해석할 수 있습니다.

- 14:15 - 14:35 **A Review of Contemporary Cancer Therapies Associated with Increased Risk of Cardiotoxicity, Including Immune Checkpoint Inhibitors**
고성애 / 영남의대
- 14:35 - 14:55 **Clinical Scenarios Associated with Increased Risk of Immune Checkpoint Inhibitor-Related Myocarditis in Patients with Cancer: Diagnosis and Management Pathways**
이소영 / 가톨릭의대
- 14:55 - 15:15 **Current and Emerging Roles of Cardiac MRI in the Evaluation and Diagnosis of Cardiotoxicity, with a Focus on Immune Checkpoint Inhibitor-Related Myocarditis**
홍유진 / 연세의대
- 15:15 - 15:35 **Nuclear Imaging in the Assessment and Diagnosis of Cardiotoxicity**
조상건 / 전남의대
- 15:35 - 15:45 **Discussion**

KSIC 1

14:15-15:45 / Rm.300B

Optimizing Antithrombotic Therapy after PCI in Patients Requiring Oral Anticoagulation

Chairperson(s) 김두일, 홍범기
 Panel 김민철, 박경우, 신은석, 정영훈, 조윤경

Learning Objective

1. 항응고 치료가 필요한 환자에서 PCI 이후 항혈전 치료 전략을 최신 근거를 바탕으로 체계적으로 살펴봅니다.
2. 시술 시기, 출혈 및 허혈 위험, 시술 복잡도에 따른 약제 선택과 치료 기간 최적화에 대한 실제 임상 적용 방안을 함께 논의해 봅니다.

- 14:15 - 14:30 **Revisiting Triple Therapy after PCI: Who Needs It, When, and for How Long?**
조현승 / 서울특별시보라매병원
- 14:30 - 14:45 **Optimizing Dual Therapy: Which DOAC and Which P2Y12 Inhibitor?**
차정준 / 고려의대
- 14:45 - 15:00 **Personalized Antithrombotic Therapy Based on Bleeding and Thrombotic Risk**
이용준 / 연세의대
- 15:00 - 15:15 **Does Procedural Complexity Matter in Antithrombotic Decision-Making?**
서정원 / 서울의대
- 15:15 - 15:30 **When Is Oral Anticoagulant Monotherapy Sufficient after PCI?**
최기홍 / 성균관의대
- 15:30 - 15:45 **Discussion**

KHRS2-SCD

14:15-15:45 / Rm.300C

Sudden Cardiac Death

Chairperson(s) 조용근, 김남호

Panel 곽혜빈, 박진선, 윤자경, 이종민, 정태완

Learning Objective

1. 돌연 심장사의 주요 비침습적 위험인자와 영상학적 마커, 유전적인 관련성을 이해합니다.
2. 다양한 심근병증에서 돌연심장사 위험인자를 파악합니다.
3. 인공지능 모델이 돌연심장사 예측에 어떻게 적용되는지 이해합니다.
4. 운동선수에서 발생하는 돌연심장사의 역학적 특징과 위험인자 관리, 원인에 대해 이해합니다.

- 14:15 - 14:30 **Non-invasive and Imaging Markers of Sudden Cardiac Death: What Are They?**
이찬희 / 영남의대
- 14:30 - 14:45 **Understand the Genetics Related to Sudden Cardiac Death**
김화중 / 가톨릭의대
- 14:45 - 15:00 **What Are the Key Risk Factors for Sudden Cardiac Death in Cardiomyopathies and the Strategies for Its Prevention?**
박한진 / 연세의대
- 15:00 - 15:15 **Exploring Multimodal AI approaches for Sudden Cardiac Death Risk Stratification Beyond Ejection Fraction**
권준명 / 세종병원
- 15:15 - 15:30 **Sudden Cardiac Death in Athletes: What Are the Epidemiology, Etiology, and Risk Factors?**
진무년 / 세종병원
- 15:30 - 15:45 **Discussion**

Rare Genetic CVD 1

14:15-15:45 / 경주힐튼호텔 파인룸(1F)

How to Diagnose Rare Genetic CVD?

Chairperson(s) 조명찬, 이상학

Panel 박준빈, 유희태, 정준철, 최종일

Learning Objective

1. To review rare inherited cardiac diseases.
2. To review diagnostic approaches for representative rare cardiac conditions.

- 14:15 - 14:35 **Familial Hypercholesterolemia**
이찬주 / 연세의대
- 14:35 - 14:55 **Brugada/Long QT Syndrome & CPVT**
정주희 / 고려의대
- 14:55 - 15:15 **Aortopathy, From Aneurysm to Dissection?**
박택규 / 성균관의대
- 15:15 - 15:35 **Hypertrophic Cardiomyopathy & Its Mimicker e.g. Amyloidosis**
심지영 / 연세의대
- 15:35 - 15:45 **Discussion**

Adult Congenital Heart Disease2

16:05-17:35 / Rm.102

Small Shunt Is Really Simple?

Chairperson(s) 이창하, 박준빈

Panel 강웅철, 김창신, 송진영, 안효석

Learning Objective

1. 성인에서 small shunt의 자연경과를 알아봅니다.
2. 성인에서 다양한 small shunt의 치료를 공부합니다.
3. 성인에서 small shunt에 동반될 수 있는 문제들을 공부합니다.

- 16:05 - 16:20 **Small ASD(Atrial Septal Defect) Is Really Benign in Adults?**
강이석 / 성균관의대
- 16:20 - 16:35 **Treatment of Small PDA in Adults**
고훈 / 부산의대
- 16:35 - 16:50 **Clinical Impact and Management of Small VSD(Ventricular Septal Defect) in Adults**
박한기 / 연세의대
- 16:50 - 17:05 **Small Shunt and Arrhythmias**
반지은 / 부천세종병원
- 17:05 - 17:20 **Small Shunt and Pulmonary Hypertension**
김이식 / 전북의대
- 17:20 - 17:35 **Discussion**

ENG Epidemiology

16:05-17:35 / Rm.104

From Evidence to Action: Global Implementation Strategies for CVD Prevention

Chairperson(s) Daichi Shimbo, Hyeon Chang Kim

Panel Eunji Kim, Min Jung Shin, Jeong-Hun Shin, Se Young Jae

Learning Objective

1. To understand real-world implementation strategies for improving blood pressure control, based on the U.S. experience.
2. To identify key barriers and enabling factors in implementing lifestyle modification strategies for CVD prevention.
3. To explore regional models and outcomes of community-based cardiovascular disease prevention programs in Korea.
4. To discuss how national surveillance data can be translated into effective public health policies and prevention strategies.

- 16:05 - 16:25 **Implementation Strategies to Improve Blood Pressure Control: U.S. Perspective**
Daichi Shimbo / Columbia University, USA
- 16:25 - 16:40 **Community-Based CVD Prevention Program: From Population Health to Practice**
Kunhee Park / Pyeongchang County Public Health Center, Korea
- 16:40 - 16:55 **Lifestyle Modification for CVD Prevention: Barriers and Strategies for Implementation**
Jung Eun Lee / Seoul National University, Korea
- 16:55 - 17:10 **From Surveillance to Impact: Applying Population Data to National CVD Strategies**
Hokyoo Lee / Yonsei Univ., Korea
- 17:10 - 17:35 **Discussion**

KSE 1

16:05-17:35 / Rm.105

Echocardiographic Hemodynamics: From Physiology to Clinical Decision-Making

Chairperson(s) 박승우

Panel 김민정, 이선화, 정혜문, 최강운

- 16:05 - 16:25 **Forward Flow & Cardiac Power**
이상현 / 부산의대
- 16:25 - 16:45 **Volume Optimization with Diastology and POCUS**
박혁진 / 전남의대
- 16:45 - 17:05 **Hemodynamic Reserve Through Exercise Echocardiography**
곽서연 / 고려의대
- 17:05 - 17:25 **Ventricular-Arterial Coupling Integrating Flow and Afterload**
손정우 / 연세원주의대
- 17:25 - 17:35 **Discussion**

ENG Cardio-Oncology

16:05-17:35 / Rm.203

Update on Cardio-Oncology 2026

Chairperson(s) Kee Sik Kim, Woo-Baek Chung

Panel Do Young Kim, Nuri Lee, So Young Lee, Yun Gyoo Lee, Jung Sun Cho

Learning Objective

1. To understand how CV biomarkers can be used for risk stratification, early detection, and monitoring of cardiotoxicity in cancer patients.
2. To recognize the role of rare pathogenic genetic variants in cardiomyopathy-related genes as contributors to individual susceptibility to CTRCD.
3. To understand how a nationwide population-based cohort study could be used in the field of cardio-oncology in Korea.

- 16:05 - 16:25 **The Role of Biomarkers in Cardio-Oncology**
Bonnie Ky / University of Pennsylvania School of Medicine, USA
- 16:25 - 16:45 **Rare Deleterious Variants in Cardiomyopathy Genes Contribute to CTRCD Pathogenesis**
Hiroshi Akazawa / Kanazawa Medical University, Japan
- 16:45 - 17:05 **Nationwide Population-Based Cardio-Oncology Research in Korea**
Jong-Chan Youn / Catholic Univ., Korea
- 17:05 - 17:35 **Discussion**

Healthcare Policy

16:05-17:35 / Rm.300B

필수의료 위기 극복을 위한 심뇌혈관질환 관리 체계의 대전환

Chairperson(s) 양동현, 정옥진
Panel 김진배, 서준, 신성희, 이종규, 이찬주

Learning Objective

1. 중앙-광역-지역 심뇌혈관질환센터의 역할 분담과, 새롭게 도입되는 인적 네트워크 기반의 진료 협력 체계를 이해합니다.
2. 중증 응급 심혈관질환에 대한 보상 강화, 이송 체계 개편 등 구체적인 지원 방안과 기대 효과를 파악합니다.
3. 지속 가능한 심뇌혈관 안전망 구축을 위해 학계와 정부가 해결해야 할 법적·제도적 선결 과제를 논의합니다.

- 16:05 - 16:25 **중앙-광역-지역 심뇌혈관질환 전달체계 구축과 중앙센터의 컨트롤 타워 역할**
이해영 / 서울의대
- 16:25 - 16:45 **중증응급 이송·전원 체계 개편과 심혈관질환 지원 정책의 방향**
유정민 / 보건복지부
- 16:45 - 17:05 **심뇌혈관질환관리법 개정 이슈와 심장질환 국가책임제의 법적 과제**
정옥진 / 가천의대
- 17:05 - 17:35 **Discussion**

KSoLA 1

16:05-17:35 / Rm.300C

New Direction of Korean Guideline for Lipid Management

Chairperson(s) 김상현, 이우제
Panel 김병식, 김현진, 장영우, 홍순준

Learning Objective

1. 한국인 1차 예방에서 최근 근거와 국내 자료를 바탕으로 LDL-C 목표 수치를 재정의하고 위험도에 따라 차등 적용하는 원칙을 이해합니다.
2. HDL-C 수치뿐 아니라 입자 특성, 동반 위험인자, 지질지표를 통합하여 동맥경화성 심혈관질환 발생 위험을 보다 정밀하게 예측하는 접근법을 습득합니다.
3. 고위험 환자에서 스타틴 단독요법의 한계를 이해하고, 초기 단계부터 에제티미브·PCSK9 억제제 등 비스타틴 제제를 병용하는 전략의 적응증과 기대 효과를 정리합니다.

- 16:05 - 16:25 **LDL-C Targets for Primary Prevention in Korean**
최종한 / 건국의대
- 16:25 - 16:45 **Risk Prediction with HDL-C**
조윤경 / 울산의대
- 16:45 - 17:05 **Early Combination of Non-Statin Therapy in High-Risk Patients**
정재훈 / 동국의대
- 17:05 - 17:35 **Discussion**

Rare Genetic CVD 2

16:05-17:35 / 경주힐튼호텔 파인룸(1F)

Up-to-date Treatment for Rare Genetic CVD

Chairperson(s) 강석민, 정진욱
Panel 김학령, 오재원, 이상언, 최정현

Learning Objective

To review the latest treatment strategies for representative rare cardiac diseases.

- 16:05 - 16:25 **Familial Hypercholesterolemia**
박재형 / 고려의대
- 16:25 - 16:45 **Pulmonary Hypertension**
허란 / 한양의대
- 16:45 - 17:05 **Hypertrophic Cardiomyopathy**
김형관 / 서울의대
- 17:05 - 17:25 **Transthyretin Amyloidosis**
이승표 / 서울의대
- 17:25 - 17:35 **Discussion**

ACC ASIA 2026

Day 2 / 18(Sat.)

ENG Valvular Diseases and Structural Interventions 4 08:00-08:45 / Rm.202

Valvular Disease Controversies: Lifetime Management and Therapy Choices

Chairperson(s) Kiyuk Chang, Kyoo Rok Han
Panel Ramesh Babu Daggubati, Jae Yeong Cho, Seong-Mi Park

- 08:00 - 08:10 **Lifetime Management in the Selection of Therapies For Patients**
Jin Sun Park / Ajou Univ., Korea
- 08:10 - 08:20 **Concomitant Valvular and Coronary Artery Diseases**
Ramesh Babu Daggubati / West Virginia University, USA
- 08:20 - 08:30 **Antithrombotic or Anticoagulation Therapies**
Sanjay Tyagi / Apollo Hospital Group, India
- 08:30 - 08:45 **Panel Discussion With Audience Question and Answer**

ENG Cardiovascular Disease Prevention 3 08:00-08:45 / Rm.205

Obesity Management in Asia: Medical, Surgical, and Emerging Therapies

Chairperson(s) Ade Meidian Ambari, Sang Hyun Ihm
Panel Kina Jeon, Minjae Yoon, Jong-Chan Youn

- 08:00 - 08:10 **Review of the 2025 ACC Expert Consensus Statement on Medical Weight Management**
Eugene Yang / University of Washington School of Medicine, USA
- 08:10 - 08:15 **Discussion**
- 08:15 - 08:25 **The Evolving Landscape of Obesity Management: Current and Emerging Therapies**
Yun Kyung Cho / Ulsan Univ., Korea
- 08:25 - 08:30 **Discussion**
- 08:30 - 08:40 **The Landscape of Metabolic Surgery in Asia**
Han Hong Lee / Catholic Univ., Korea
- 08:40 - 08:45 **Discussion**

2
Day

ACC ASIA 2026 TOGETHER
WITH
KSC SPRING CONFERENCE

18(Sat.)

ENG Cardiac Arrhythmias 2

08:00-08:45 / Rm.300A

Advances in Stroke Prevention For Atrial Fibrillation: Evidence and Innovation

Chairperson(s) Eue-Keun Choi
Panel Andrea M. Russo, Jum Seok Ko, Hyo-Jeong Ahn

- 08:00 - 08:10 **New Evidence of Stroke Prevention in Patients With AFib and CAD**
Hee Tae Yu / Yonsei Univ., Korea
- 08:10 - 08:15 **Panel Discussion With Audience Question and Answer**
- 08:15 - 08:25 **What's New with Oral Anticoagulants: Factor XI/X1a Inhibitors**
Andrea M. Russo / Cooper Medical School of Rowan University, USA
- 08:25 - 08:30 **Panel Discussion With Audience Question and Answer**
- 08:30 - 08:40 **Recent Update on Anticoagulation After Successful AFib Ablation**
Boyoung Joung / Yonsei Univ., Korea
- 08:40 - 08:45 **Panel Discussion With Audience Question and Answer**

ENG Plenary 3

08:55-09:40 / Rm.300A

Top Clinical Trials

Chairperson(s) Bonnie Ky, Myeong Ki Hong
Panel Ki Hong Choi, Jiesuck Park, So-Ryoung Lee

- 08:55 - 08:56 **Introduction**
- 08:56 - 09:01 **Ultrasound-facilitated Catheter-directed Thrombolysis Vs Anticoagulation Alone for Acute Intermediate-high-risk Pulmonary Embolism: Primary Results of the HI-PEITHO Randomized Clinical Trial**
Ramesh Babu Daggubati / West Virginia University, USA
- 09:01 - 09:07 **Discussion**
- 09:07 - 09:12 **Outcomes in Patients With Atrial Fibrillation Randomized to Receive Left Atrial Appendage Closure or Oral Anticoagulation: Primary Results of the CHAMPION-AF Clinical Trial**
Andrea M. Russo / Cooper Medical School of Rowan University, USA
- 09:12 - 09:18 **Discussion**
- 09:18 - 09:23 **Controlled Trial Of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading (CHIP-BCIS3)**
Kwan Seung Lee / Mayo Clinic Arizona, USA
- 09:23 - 09:29 **Discussion**
- 09:29 - 09:34 **Intensive Low-density Lipoprotein Cholesterol Targeting in Patients With Atherosclerotic Cardiovascular Disease**
Byeong-Keuk Kim / Yonsei Univ., Korea
- 09:34 - 09:40 **Discussion**

ENG Cardiac Arrhythmias 3

(Joint Society Session with Korean Heart Rhythm Society)

09:50-10:35 / Rm.205

Ventricular Tachycardia in Cardiomyopathy: Mapping, Genetics, and Imaging

Chairperson(s) Andrea M. Russo, Hui Nam Pak
Panel Sang Weon Park, Min Soo Cho, Jin-Kyu Park

- 09:50 - 10:05 **VT Localization: QRS Discrepant From VT Origin**
Ju Youn Kim / Sungkyunkwan Univ., Korea
- 10:05 - 10:12 **Panel Discussion With Audience Question and Answer**
- 10:12 - 10:27 **Recent Update on VT Mapping and Ablation in ARVC**
Kyoung-Min Park / Sungkyunkwan Univ., Korea
- 10:27 - 10:35 **Panel Discussion With Audience Question and Answer**

ENG Cardiovascular Disease Prevention 4

09:50-10:35 / Rm.300A

Global Perspectives on Blood Pressure Guidelines: ACC/AHA, KSH, and JSH

Chairperson(s) Kwang-il Kim, Eugene Yang
Panel Ade Meidian Ambari, Dae Young Cheon, Eui-Soon Kim

- 09:50 - 10:00 **Overview of AHA/ACC Multi-Society Blood Pressure Guideline**
Eugene Yang / University of Washington School of Medicine, USA
- 10:00 - 10:10 **Korean Society of Hypertension (KSH) BP Guideline Review**
Sung Ha Park / Yonsei Univ., Korea
- 10:10 - 10:20 **Japanese Society of Hypertension (JSH) Guidelines For the Management of Elevated Blood Pressure and Hypertension**
Junya Ako / Kitasato University, Japan
- 10:20 - 10:35 **Panel Discussion With Audience Question and Answer**

ENG Cardiac Arrhythmias 4
(Joint Society Session with Korean Heart Rhythm Society)

10:45-11:30 / Rm.205

Device Therapies in Heart Failure: Innovations and Clinical Impact

Chairperson(s) Seil Oh, Seok-Min Kang
Panel Jaewon Oh, Sung-Hee Shin, Min Kim

- 10:45 - 10:55 **Recent Advancement on Prevention of Sudden Cardiac Death in HF Patients**
Lae Young Jung / Jeonbuk National Univ., Korea
- 10:55 - 11:00 **Panel Discussion With Audience Question and Answer**
- 11:00 - 11:10 **New Insight on Pacing-Induced Cardiomyopathy**
So-Ryoung Lee / Seoul National Univ., Korea
- 11:10 - 11:15 **Panel Discussion With Audience Question and Answer**
- 11:15 - 11:25 **CRT vs Conduction System Pacing For HF With Reduced or Mildly Reduced EF**
Pugazhendhi Vijayaraman / Geisinger Heart Institute, USA
- 11:25 - 11:30 **Panel Discussion With Audience Question and Answer**

ENG Coronary Interventions and Ischemic Heart Diseases 4 10:45-11:30 / Rm.300A

Personalizing Antiplatelet Therapy: Risk, Genetics, and Regional Insights

Chairperson(s) Kyung Woo Park, Kwan Seung Lee
Panel Rodney Jimenez, Sung Eun Kim, Ramesh Babu Daggubati

- 10:45 - 10:55 **Should All Patients Undergo Standard DAPT De-escalation Following Acute Myocardial Infarction?**
Chan Joon Kim / Catholic Univ., Korea
- 10:55 - 11:00 **Panel Discussion With Audience Question and Answer**
- 11:00 - 11:10 **Bleeding / Thrombotic Risk Profiles of East Asian Patients**
Jeehoon Kang / Seoul National Univ., Korea
- 11:10 - 11:15 **Panel Discussion With Audience Question and Answer**
- 11:15 - 11:25 **In the Era of De-Escalation Is There a Role for CYP2C19 Genetic Testing?**
Roxana Mehran / Icahn School of Medicine at Mount Sinai, USA
- 11:25 - 11:30 **Panel Discussion With Audience Question and Answer**

ENG Special Topics 5

11:40-12:20 / Rm.202

Women in Cardiology: Pathways to Success and Leadership

Chairperson(s) Il Suk Sohn, Mayanna Lund
Panel Seong-Mi Park, Roxana Mehran, Bonnie Ky, Andrea M. Russo, Cynthia Taub

ENG Multimodal Imaging 3

12:35-13:20 / Rm.202

Top Three Innovations or Hot Topics in Multimodal Imaging

Chairperson(s) Cynthia Taub, Sang-Chol Lee
Panel Sung Min Ko, In-Cheol Kim, Jae K. Oh

- 12:35 - 12:45 **Top Three Innovations or Hot Topics in CMR**
Eui-Young Choi / Yonsei Univ., Korea
- 12:45 - 12:55 **Top Three Innovations or Hot Topics in Echocardiography**
Cynthia Taub / SUNY Upstate Medical University, USA
- 12:55 - 13:05 **Top Three Innovations or Hot Topics in CT**
Tiffany Chen / University of Washington, USA
- 13:05 - 13:20 **Panel Discussion With Audience Question and Answer**

ENG Special Topics 6

12:35-13:20 / Rm.300A

Digital Health in Cardiology: AI, Wearables, and Imaging

Chairperson(s) Young Hak Kim, Kwan Seung Lee
Panel Harlan M. Krumholz, Kin-Lam Tsui, Soonil Kwon

- 12:35 - 12:45 **AI in Wearables For Population Health**
Joon-Myoung Kwon / Sejong Hospital, Korea
- 12:45 - 12:55 **AI in Echo Imaging**
Federico M. Asch / MedStar Health and Georgetown University, USA
- 12:55 - 13:05 **AI in CT Plaque Analysis**
Bon-Kwon Koo / Seoul National Univ., Korea
- 13:05 - 13:20 **Panel Discussion With Audience Question and Answer**

ENG Multimodal Imaging 4

13:30-14:15 / Rm.202

From Leads to Leaflets: Multimodality Imaging in the Diagnosis of Endocarditis

Chairperson(s) William Kong, Hae Ok Jung
Panel Smonporn Boonyaratavej Songmuang, Dae-Hee Kim, ACC

- 13:30 - 13:40 **CIED-related Infective Endocarditis**
Cynthia Taub / SUNY Upstate Medical University, USA
- 13:40 - 13:50 **Prosthetic Valve Endocarditis**
William Kong / The National University Heart Centre Singapore, Singapore
- 13:50 - 14:00 **Non-bacteria Thrombotic Endocarditis**
Hyun-Jung Lee / Seoul National Univ., Korea
- 14:00 - 14:15 **Panel Discussion With Audience Question and Answer**

ENG Heart Failure and Cardiomyopathies 4

13:30-14:15 / Rm.300A

Acute Heart Failure: Managing Cardiorenal Syndrome and Shock

Chairperson(s) Seok-Min Kang, Mayanna Lund
Panel Ji-Hun Jang, Min-Seok Kim, Aekarach Ariyachaipanich

- 13:30 - 13:40 **Defining and Overcoming Diuretic Resistance**
Aekarach Ariyachaipanich / Chulalongkorn University, Thailand
- 13:40 - 13:45 **Panel Discussion With Audience Question and Answer**
- 13:45 - 13:55 **Cardiorenal Syndrome: Pathophysiology to Intervention**
Jennifer A. Cowger / Michigan State University, USA
- 13:55 - 14:00 **Panel Discussion With Audience Question and Answer**
- 14:00 - 14:10 **Cardiogenic Shock: Fundamentals of Managing Shock Due to Acute Myocardial Infarction vs. Chronic Heart Failure**
Jeong Hoon Yang / Sungkyunkwan Univ., Korea
- 14:10 - 14:15 **Panel Discussion With Audience Question and Answer**

ENG Plenary 4

14:25-15:10 / Rm.300A

STEMI Care Delivery: Global Disparities and Solutions

Chairperson(s) Hyo-Soo Kim, Kwan Seung Lee
Panel Jin Man Cho, Dong Oh Kang, Hyung Joon Joo

- 14:25 - 14:35 **High Income Country**
Jang-Whan Bae / Good Samsun Hospital, Korea
- 14:35 - 14:45 **Lower Middle Income Country**
ACC
- 14:45 - 14:55 **Lower Middle Income Country**
Sanjay Tyagi / Apollo Hospital Group, India
- 14:55 - 15:10 **Panel Discussion With Audience Question and Answer**

ENG Convocation and Closing Ceremony

15:20-16:05 / Rm.300A

Presenters Kwan Seung Lee, Seok-Min Kang, Roxana Mehran

KSC SPRING CONFERENCE

Day 2 / 18(Sat.)

Cardiogenic Shock

08:00-09:30 / Rm.102

Modern Management of Cardiogenic Shock

Chairperson(s) 조명찬, 유철웅

Panel 김아람, 김지훈, 배대환, 안철민, 차지현

Learning Objective

1. To recognize and stage cardiogenic shock using contemporary diagnostic and risk stratification frameworks.
2. To apply phenotype-based pharmacologic strategies and identify the limits of medical therapy in cardiogenic shock.
3. To select appropriate mechanical circulatory support in AMI-related cardiogenic shock, with a practical comparison of Impella and VA-ECMO.

08:00 - 08:15 **Early Recognition and Risk Stratification of Cardiogenic Shock**
이진호 / 경희의대

08:15 - 08:30 **Hemodynamic Phenotypes of Cardiogenic Shock**
김범성 / 건국대의대

08:30 - 08:45 **Pharmacologic Management of Cardiogenic Shock**
김민철 / 전남의대

08:45 - 09:00 **Impella vs. VA-ECMO in AMI-Related Cardiogenic Shock**
양정훈 / 성균관대의대

09:00 - 09:15 **Shock Team & Shock Center: Does System Matter?**
강지훈 / 서울의대

09:15 - 09:30 **Discussion**

Cardiac Surgery

08:00-09:30 / Rm.104

A Deadly Duo: Valvular Heart Disease and Atrial Fibrillation

Chairperson(s) 제형근, 이삭

Panel 김홍래, 박수진, 박한진, 표원경

Learning Objective

1. 판막성 심방세동의 최신 가이드라인과 임상증거에 대해 알아봅니다.
2. 판막성 심방세동의 항응고요법에 대해 숙지합니다.
3. 판막질환과 심방세동의 동시 수술의 장단점 및 좌심실이 절제술의 효과에 대해 알아봅니다.

08:00 - 08:15 **The Paradigm Shift in Valvular AF: Contemporary Guidelines and Evidence**
김대훈 / 연세의대

08:15 - 08:30 **Anticoagulation Strategies in Valvular AF: Beyond Warfarin**
심재민 / 고려의대

08:30 - 08:45 **Impact of Surgical Maze Procedure on Survival and Stroke Prevention in Valvular AF**
김호진 / 울산의대

08:45 - 09:00 **Restorin Sinus Rhythm: Clinical Efficacy of Surgery in Valvular AF Patients**
노선균 / 한양대의대

09:00 - 09:15 **Left Atrial Appendage Exclusion Strategies in Valvular AF**
정수련 / 성균관대의대

09:15 - 09:30 **Discussion**

KSE 2

08:00-09:30 / Rm.105

Imaging-Guided Approach to Cardiomyopathies: From Diagnosis to Treatment Guidance

Chairperson(s) 최지용

Panel 김혜미, 남종호, 이주희, 황지원

08:00 - 08:20 **Echo Red Flags: When to Suspect Cardiomyopathies Rather Than Concentric LVH**
신성희 / 인하의대

08:20 - 08:40 **Multimodality Imaging in Suspected Cardiomyopathy: When to Go Beyond Echocardiography**
최의영 / 연세의대

08:40 - 09:00 **Imaging-Guided Assessment of Treatment Response in Cardiomyopathy: HCM**
이사민 / 울산의대

09:00 - 09:20 **Imaging-Guided Assessment of Treatment Response in Cardiomyopathy: RCM**
박진오 / 인제대의대

09:20 - 09:30 **Discussion**

ENG Vascular Research 1

08:00-09:30 / Rm.203

2026 How to Measure Vascular Health

Chairperson(s) Ki Chul Sung, Byoung Kwon Lee

Panel Suk Min Seo, Heesun Lee, Hyemoon Chung, Jun Hwan Cho, Seok-Jae Hwang

Learning Objective

1. To understand the conceptual framework for assessing vascular health with a focus on aortic stiffness, and to explain the limitations of traditional blood pressure-centered evaluation.
2. To understand how various vascular function indices-including hemorheology, microvascular function, and imaging-based assessments-account for residual cardiovascular risk.
3. To critically evaluate the clinical significance and real-world applicability of emerging vascular health assessment methods utilizing imaging, AI, and digital health technologies.

08:00 - 08:15 **Aortic Stiffness as the Foundation of Vascular Health Assessment**

Jaehoon Chung / Dongguk Univ., Korea

08:15 - 08:30 **Rheology as a Missing Link in Cardiovascular Disease**

Young-Hoon Jeong / Chung-Ang Univ., Korea

08:30 - 08:45 **Imaging-Based Assessment of Vascular Health**

Wei-Chun Huang / Pingtung Christian Hospital National Sun Yat-sen University, Taiwan

08:45 - 09:00 **Residual Vascular Risk: Why Events Occur Despite Good Control**

Nuntakorn Thongtang / Mahidol University, Thailand

09:00 - 09:15 **AI and Digital Health for Vascular Health**

SungA Bae / Yonsei Univ., Korea

09:15 - 09:30 **Discussion**

KSIC 2

08:00-09:30 / Rm.300B

Managing Coronary Calcification in PCI

Chairperson(s) 권현철, 김희열

Panel 김병국, 남창욱, 이봉기, 임영효, 홍영준

Learning Objective

1. 관상동맥 석회화 병변에서 PCI를 시행할 때 석회화의 형태와 분포에 따른 치료 전략의 차이를 살펴봅니다.
2. 최신 근거와 증례를 통해 적절한 기기 선택과 intravascular imaging의 중요성을 살펴보고자 합니다.

08:00 - 08:15 **Understanding Coronary Calcium: Morphology, Distribution, and Clinical Implications**

김동기 / 인제대

08:15 - 08:30 **Morphology-Based Device Selection and Procedural Techniques: Rotational Atherectomy**

김남균 / 경북대

08:30 - 08:45 **Morphology-Based Device Selection and Procedural Techniques: Orbital Atherectomy**

이관용 / 가톨릭대

08:45 - 09:00 **Morphology-Based Device Selection and Procedural Techniques: IVL**

송영빈 / 성균관대

09:00 - 09:15 **Intravascular Imaging-Guided Calcium Assessment and Optimization**

이상엽 / 중앙대

09:15 - 09:30 **Discussion**

Education Workshop 1 - Arrhythmia

08:00-09:30 / Rm.300C

Recent Therapeutic Approaches in Arrhythmias

Chairperson(s) 이명용, 오세일
Panel 김민, 김예지, 박윤정, 정태완

Learning Objective

- 1 Physiologic atrial and ventricular pacing의 최신 개념과 임상적 의미를 이해합니다.
- 2 최신 ablation energy와 ablation technologies의 근거와 임상적 적용 가능성을 심방세동을 넘어 고찰합니다.
- 3 Inherited channelopathies의 최신 개념을 바탕으로 유전적 진단, 위험도 평가 및 맞춤형 치료 전략의 임상적 의미를 이해합니다.

- 08:00 - 08:15 **Current Status of Physiologic Pacing: Bachmann's Bundle Pacing and Left Bundle Branch Pacing**
조민수 / 울산의대
- 08:15 - 08:30 **Current Status of Leadless Pacemakers: Devices, Indications, and Limitations**
황종민 / 계명대의대
- 08:30 - 08:45 **Evolution of Technologies for AF Ablation**
이대인 / 고려의대
- 08:45 - 09:00 **Mapping and Ablation Technologies for Ventricular Arrhythmia**
엄재선 / 연세의대
- 09:00 - 09:15 **Inherited Channelopathies**
최영 / 가톨릭의대
- 09:15 - 09:30 **Discussion**

Cardiovascular Genome and Precision Medicine

09:50-11:20 / Rm.102

Deep Dive to Genetic Testing, What, When, How & Who?

Chairperson(s) 김덕경, 이상학
Panel 김미주, 문인기, 박미현, 이주연

Learning Objective

1. 유전자 검사 기본에 대해 리뷰합니다.
2. 어떤 때 유전자 검사를 하고, 그 결과를 어떻게 해석하고 WES / WGS 필요한 상황에 대해 리뷰합니다.

- 09:50 - 10:10 **When Do I Check Genetic Test?**
오재원 / 연세의대
- 10:10 - 10:30 **How to Interpret Genetic Test Report?**
김만진 / 서울의대
- 10:30 - 10:50 **Who Need Whole Exome / Genome Sequencing?**
서고훈 / 3Billion
- 10:50 - 11:20 **Discussion**

ENG KPHS 1

09:50-11:20 / Rm.104

Rethinking 'Simple' Heart Defects: Advances in Diagnosis and Treatment

Chairperson(s) Jo Won Jung, Cheul Lee
Panel Yujin Kwak, Hye Won Kwon, Eung Re Kim, Jae Hong Lim, Gwang-Jun Choi

Learning Objective

1. To review long-term complications and key considerations during follow-up in common but clinically important simple congenital heart diseases.
2. To determine the appropriate duration of follow-up after treatment of ASD, VSD, or small VSD, and to identify potential complications to monitor.
3. To discuss surgical and interventional treatment strategies for simple congenital heart disease, including surgery versus intervention.

- 09:50 - 10:05 **VSD(Ventricular Septal Defect) - Have We Figured It Out Yet?**
Leo Lopez / Stanford University, USA
- 10:05 - 10:20 **The Fate of VSD: How Long Should We Follow-up? - Small VSD vs Repaired VSD**
Lucy Youngmin Eun / Yonsei Univ., Korea
- 10:20 - 10:35 **The Fate of Repaired ASD: How Long Should We Follow-up?**
Jihye You / Jeonbuk National Univ., Korea
- 10:35 - 10:50 **Surgical Perspectives on "Simple" Congenital Heart Defects: Are They Really Simple?**
Chun Soo Park / Ulsan Univ., Korea
- 10:50 - 11:05 **Contemporary Catheter-Based Strategies for Simple Congenital Heart Defects**
Seulgi Cha / Ulsan Univ., Korea
- 11:05 - 11:20 **Discussion**

ENG KSE 3

09:50-11:20 / Rm.105

Echo on the Frontlines: Here, There, and Everywhere

Chairperson(s) Hae Ok Jung, Goo-Yeong Cho
Panel Dae-Young Kim, Jin Kyung Oh, Nuri Lee, In-Chang Hwang, Alex Lee

- 09:50 - 10:10 **AI-Powered Echo: Bridging the Gap from Labs to the Frontlines**
Jae K. Oh / Mayo Clinic, USA
- 10:10 - 10:30 **Echo in the Oncology Clinic: Safeguarding the Heart**
Woo-Baek Chung / Catholic Univ., Korea
- 10:30 - 10:50 **Echo in the ICU: Bedside Decisions in Critical Care**
Cynthia Taub / SUNY Upstate Medical Univ., USA
- 10:50 - 11:10 **Echo in the Stroke Unit: Cardiac Clues Behind Stroke**
Mi-Na Kim / Korea Univ., Korea
- 11:10 - 11:20 **Discussion**

KSHF 2

09:50-11:20 / Rm.203

Advanced Therapies, Palliation, and Human Dignity in Stage D Heart Failure

Chairperson(s) 박대균, 유병수

Panel 김안철, 윤민재, 이선기, 정성호

Learning Objective

1. Stage D 심부전에서 LVAD의 발전에 따라서 Benefit을 얻을 환자 Burden만 될 환자를 selection을 하는 것도 변화되고 최신 업데이트된 데이터를 통해 함께 논의해봅니다.
2. Stage D 심부전에서 적극적 치료의 한계를 인식하고, 완화의료(palliative care)를 포함한 환자 중심 치료 전략을 임상 상황에 맞게 선택할 수 있습니다.
3. 심부전 환자의 완화의료에 어떻게 정책에 반영되어야 할지에 대해서 논의합니다.

- 09:50 - 10:05 **(ENG) Up-to-Date Management of Stage D HF in Asia**
Michael Ka Lam Wong / Cardiac Medical Unit, Grantham Hospital, Hong Kong
- 10:05 - 10:20 **LVAD in Korea: Insight from the Korean Registry**
최진오 / 성균관대의대
- 10:20 - 10:35 **Palliative Care in End-Stage Heart Failure**
이해영 / 서울의대
- 10:35 - 10:50 **ICD Deactivation in End-Stage Heart Failure: Ethical and Clinical Considerations**
김아람 / 울산의대
- 10:50 - 11:05 **How to Apply Palliative Care/Hospice in Heart Failure Patients**
유신혜 / 서울의대
- 11:05 - 11:20 **Discussion**

Smart Health

09:50-11:20 / Rm.300B

Human-AI Collaboration in Cardiovascular Digital Health Care: Opportunities, Limits, and Trust

Chairperson(s) 김영학, 강현재

Panel 김용철, 이승준, 조영진, 최종일

Learning Objective

1. 전반적인 AI and digital health 의 최신 동향을 들어볼 수 있는 세션으로 준비했습니다.
2. 향후 인간대 AI의 사회적 역할, AI의 신뢰성 등 철학적인 내용도 고찰해 보고자 합니다.

- 09:50 - 10:05 **AI in Cardiac Image Acquisition and Analysis: Current Developments**
장혁재 / 연세의대
- 10:05 - 10:20 **Advancements in AI ECG**
김경수 / Medical AI
- 10:20 - 10:35 **Wearable Devices: Current Status and Future Perspectives**
김윤기 / 고려의대
- 10:35 - 10:50 **Human Doctors vs. AI for Clinical Consultation**
권주성 / 서울의대
- 10:50 - 11:05 **Credibility of AI**
김충기 / 이화의대
- 11:05 - 11:20 **Discussion**

Education Workshop 2 - Hypertension

09:50-11:20 / Rm.300C

Recent Issues in Hypertension

Chairperson(s) 임상현, 나승운

Panel 김성수, 손일석, 신정훈, 이장훈

Learning Objective

1. 진단과 치료의 핵심 사항들을 리뷰합니다.
2. 고혈압의 최신 트렌드와 발전 상황도 살펴봅니다.

- 09:50 - 10:05 **Core Essentials of the Clinical Practice Guideline**
이은미 / 동국대의대
- 10:05 - 10:20 **Importance of Out-of-office BP Monitoring**
정중화 / 조선의대
- 10:20 - 10:35 **AI-driven Personalized Management in Hypertension**
배성아 / 연세의대
- 10:35 - 10:50 **Management Strategies for Resistant Hypertension**
나진오 / 고려의대
- 10:50 - 11:05 **Fixed Initial Low-dose Triple or Quadruple Combination Therapy for Hypertension**
박성하 / 연세의대
- 11:05 - 11:20 **Discussion**

Scientific Session [Daiichi Sankyo/Daewoong]

11:40-12:20 / Rm.105

Evidence-Based Management of Atrial Fibrillation and Hypertension

Chairperson(s) 박형욱, 최성훈

11:40 - 12:00 **Evidence-Based Anticoagulation in Elderly AF**

이찬희 / 영남의대

12:00 - 12:20 **Optimizing Hypertension Treatment with Olmesartan BP Control & CV Protection**

김학령 / 서울의대

Scientific Session [JW Pharm]

11:40-12:20 / Rm.203

Strategic Management for Cardiovascular Prevention: Balancing Efficacy and Safety

Chairperson(s) 임상현, 박철수

11:40 - 12:00 **Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy**

추은호 / 가톨릭의대

12:00 - 12:20 **Integrated Management of Hypertension and Dyslipidemia for Cardiovascular Disease Prevention**

안효석 / 가톨릭의대

Scientific Session [Yuhan]

11:40-12:20 / Rm.205

The New Era of Lipid Management: Translating 2026 ACC/AHA Guidelines into Practice with Rosuvastatin Plus Ezetimibe for Intensive LDL-C Targeting

Chairperson(s) 채인호, 김병국

11:40 - 12:00 **Evolution of Dyslipidemia Guidelines with the 2026 ACC/AHA Updates: Finding the Role of Rosuvastatin Plus Ezetimibe**

박재형 / 고려의대

12:00 - 12:20 **Paving the Road for Optimal LDL-C Management: New Evidence on Intensive LDL-C Targeting**

이용준 / 연세의대

Scientific Session [Celltrion Pharm/Daewon]

11:40-12:20 / Rm.300A

Strategies for Managing Hypertension

Chairperson(s) 유병수, 박성하

11:40 - 12:00 **What to Consider for 24hr BP Control**

김대희 / 울산의대

12:00 - 12:20 **Advanced Combination Therapy in Hypertension: The Role of Azilsartan-Amlodipine**

이찬주 / 연세의대

Scientific Session [Viatris]

11:40-12:20 / Rm.300B

From Risk Recognition to Therapeutic Decision: Statin Selection Beyond LDL-C

Chairperson(s) 정진욱, 한주용

11:40 - 12:00 **Effective Therapies for High-Risk Dyslipidemia Patients Who Need Aggressive LDL-C Lowering**

강도윤 / 울산의대

12:00 - 12:20 **Consideration of Renal Safety in Dyslipidemia Patients: Why It's Essential**

강지훈 / 서울의대

Scientific Session [Sky Labs]

11:40-12:20 / Rm.300C

Cuffless BP Monitoring: Evidence to Experience

Chairperson(s) 강석민, 김광일

11:40 - 12:00 **Cuffless BP Monitoring and Current Guidelines: Where Are We Now?**
양정훈 / 성균관대

12:00 - 12:20 **Clinical Evidence of CART BP in Routine Hypertension Care: Where Do We Go?**
신정훈 / 한양대

KSoLA 2

12:35-14:05 / Rm.102

Beyond LDL-C: Residual Risk and Competing Priorities

Chairperson(s) 최동훈, 이상학

Panel 박재형, 조현승, 차정준, 홍준화

Learning Objective

1. LDL-C 목표 도달 이후 남은 잔여위험과 Lp(a), oxidized phospholipids의 역할 및 잠정적 치료 전략을 이해합니다.
2. 중성지방 및 잔여콜레스테롤 표적 치료에서 ANGPTL3, APOC3 억제제의 기전, 임상 근거, 잠재적 적용 환자군을 정리합니다.
3. hs-CRP가 높은 환자에서 염증 표적 치료와 지질강화 치료의 우선순위와 병용 및 순차 투여 전략을 비교합니다.

12:35 - 12:55 **Lp(a) and Oxidized Phospholipids: What to Do While We Wait for Dedicated Therapies**
이장훈 / 경북의대

12:55 - 13:15 **ANGPTL3 and APO3 Inhibition for Triglyceride-Rich Lipoproteins and Remnant Cholesterol**
배재현 / 서울의대

13:15 - 13:35 **Inflammation vs Lipids: Sequencing Therapies When hs-CRP Is High**
우종신 / 경희의대

13:35 - 14:05 **Discussion**

ENG KPHS 2

12:35-14:05 / Rm.104

Left-sided Valve Issues in Congenital Heart Diseases

Chairperson(s) Tae Gook Jun, Hyoung Doo Lee

Panel Chang Sin Kim, Hyungtae Kim, Joo Won Lee, Woo Seong Chang, Hwa Jin Cho

Learning Objective

1. To review imaging assessment methods and the indications for medical and surgical management of left-sided congenital valvular heart disease.
2. To review surgical treatment strategies and outcomes of left-sided congenital valvular heart disease.
3. Through this session, we aim to reach a consensus on the management of left-sided heart disease in pediatric and adolescent patients.

12:35 - 12:50 **3D Echo and Advanced Imaging Evaluation of the Congenital Atrioventricular Valve Diseases**
Leo Lopez / Stanford University, USA

12:50 - 13:05 **Left-Sided Valve Challenges in Pediatric Patients: When to Intervene?**
Seung Min Baek / Seoul National Univ., Korea

13:05 - 13:20 **Mitral Valve Reconstruction in CHD(Congenital Heart Disease): Selection of Surgical Strategies & Durability**
Yu Rim Shin / Yonsei Univ., Korea

13:20 - 13:35 **Aortic Valve Repair in Congenital Heart Disease: Growth-Compatible Techniques and Long-Term Durability**
Eun Seok Choi / Ulsan Univ., Korea

13:35 - 13:50 **Atrioventricular Valve Management in Single Ventricle: Surgical Indication and Outcome**
Ji-Hyuk Yang / Sungkyunkwan Univ., Korea

13:50 - 14:05 **Discussion**

KHRS3-CIED

12:35-14:05 / Rm.105

Optimal Strategies for Cardiac Pacing Therapy: From Physiologic Pacing to Long-Term Complication Management (Case-Based)

Chairperson(s) 오용석, 최종일

Panel 이경연, 이영수, 이지현, 임성일, 최윤영

Learning Objective

1. 다양한 심방 페이스 위치(Atrial Pacing Sites)의 생리학적 이점을 이해하고, 특히 Bachmann Bundle Pacing의 임상 적용을 고려할 수 있습니다.
2. Conduction System Pacing (CSP)시술에 있어서 환자 특성 (적응증, 해부학적 특성 [chamber size, structural heart disease 동반 여부 등]) 에 따라 시술 성공률을 높일 수 있는 맞춤형 시술 전략을 논의합니다.
3. Leadless Pacemaker (LPM)의 장점과 한계를 이해하고, Leadless VDD/LPM-CRT 등 발전된 기술을 기반으로 LPM을 고려해야 할 명확한 환자군을 선별할 수 있습니다.
4. 장기 박동기 환자 추적관찰 중 발생하는 심부전(PICM 포함)과 심첨판 역류증(TR)의 발생 기전을 설명하고, 약물 치료, CRT 업그레이드, 경피적 심첨판 시술 등을 포함한 포괄적인 관리 전략을 증례 기반으로 수립할 수 있습니다.

12:35 - 12:50 Atrial Pacing Lead, Where Is the Optimal Site for Its Placement?

황종민 / 계명대

12:50 - 13:05 Are There Patient-Specific Tailored Strategies for CSP Implantation?

박영준 / 고려대

13:05 - 13:20 In Which Patients Should a Leadless Pacemaker Be Considered?

김인수 / 연세대

13:20 - 13:35 CIEDs in the Operating Room: Which Complications Require Surgical Management?

강윤진 / 서울대

13:35 - 13:50 How Should We Manage Heart Failure and Tricuspid Valve Regurgitation that Develop During the Follow-up of Pacemaker Patients?

김성수 / 조선대

13:50 - 14:05 Discussion

Vascular Research 2

12:35-14:05 / Rm.203

2026 How to Manage Peripheral Artery Disease

Chairperson(s) 이무용, 조은주

Panel 김수홍, 윤영진, 이승재, 이재환, 조정환

Learning Objective

1. Peripheral artery disease를 국소 하지 질환이 아닌 전신 혈관 질환의 표현형으로 이해하고, 환자 예후 관점에서 그 임상적 의미를 설명할 수 있습니다.
2. ABI를 포함한 진단 도구의 한계를 인지하고, 증상과 기능 평가를 통합하여 PAD의 중증도와 치료 필요성을 판단할 수 있습니다.
3. 가이드라인에 근거한 약물 치료, 운동 치료, 재혈관화 전략의 적절한 적용 시점을 구분하고, 환자 특성에 따른 치료 전략을 선택할 수 있습니다.

12:35 - 12:50 Guideline-Based Management of Peripheral Artery Disease

권주성 / 서울의대

12:50 - 13:05 Redefining PAD: A Marker of Systemic Vascular Disease

최강운 / 영남대

13:05 - 13:20 How to Diagnose and Functionally Assess Peripheral Artery Disease

박택규 / 성균관대

13:20 - 13:35 When and How to Revascularize: Choosing the Right Strategy for the Right Patient

장지용 / 국민건강보험 일산병원

13:35 - 13:50 Why Exercise Matters in Peripheral Artery Disease

이종영 / 한림대

13:50 - 14:05 Discussion

Cardio-cerebrovascular Disease Prevention

12:35-14:05 / Rm.205

High-Risk Pregnancy and Lifelong Cardiovascular Health: From Early Risk to Prevention

Chairperson(s) 임상현, 최성훈
 Panel 김의순, 김정선, 이진배, 이호규, 임현정, 전기나

Learning Objective

1. 고위험 임신과 산모 및 자녀의 장기 심혈관질환 위험 사이의 역학적 연관성을 이해합니다.
2. 태반 병리 소견이 미래 심혈관질환 위험을 반영하는 생물학적 기전으로서 갖는 의미를 이해합니다.
3. 고위험 임신 환자를 체계적으로 추적·관리하기 위한 국가 및 병원 단위 레지스트리 구축의 필요성과 가능성을 인식합니다.

- 12:35 - 12:55 **The Epidemiology of High-Risk Pregnancy and Future Cardiovascular Risk**
 김현창 / 연세의대
- 12:55 - 13:15 **Placental Pathology: Clues to Future Cardiovascular Disease**
 김은나 / 서울의대
- 13:15 - 13:35 **Building a High-Risk Pregnancy Registry: Are We Ready for Lifelong Prevention?**
 고현선 / 가톨릭의대
- 13:35 - 14:05 **Discussion**

KSIC 3

12:35-14:05 / Rm.300B

Cross Specialty: Cutting-Edge Issues in TAVR 2026

Chairperson(s) 채인호, 고영국
 Panel 김은경, 박덕우, 양태현, 이상록, 이철현

Learning Objective

1. 2026년 현재 TAVR 분야의 최전선에서 다뤄지고 있는 주요 이슈들을 한 자리에서 조망하고 논의할 귀중한 기회입니다.
2. 최근 발표된 cutting-edge 연구들을 중심으로, TAVR 진료 패러다임의 변화와 향후 방향성을 다루는 자리입니다.

- 12:35 - 12:50 **To PCI or Not to PCI: Obstructive CAD in the Peri-TAVR Setting**
 황병희 / 가톨릭의대
- 12:50 - 13:05 **Minimally Invasive Surgical Explantation for Failed TAVR Valves**
 유재석 / 울산의대
- 13:05 - 13:20 **Optimal Antithrombotic Therapy after TAVR: With or Without Indication for Anticoagulation**
 강도윤 / 울산의대
- 13:20 - 13:35 **Long-Term Performance and Durability of TAVR Valves**
 홍성진 / 연세의대
- 13:35 - 13:50 **TAVR in Low-Flow, Low-Gradient Aortic Stenosis: Indications and Outcomes**
 한정규 / 서울의대
- 13:50 - 14:05 **Discussion**

Education Workshop 3 - Heart Failure

12:35-14:05 / Rm.300C

Diagnosis and Treatment Beyond HFrEF

Chairperson(s) 유병수, 김계훈
 Panel 손정우, 정미향, 조동혁, 조재영

Learning Objective

1. ATTR 심근병증과 비후성 심근병증에서 심초음파를 활용한 진단 및 감별의 핵심 포인트를 이해하고, 임상에서의 역할과 가치를 인식합니다.
2. 최신 가이드라인에 근거한 이완기 기능 평가의 주요 지표와 해석 원칙을 숙지하고, 다양한 임상 상황에서 이를 실제 임상에 적용합니다.
3. 최신 판막질환 가이드라인의 주요 변화와 핵심 메시지를 이해하고, 심초음파를 기반으로 한 적절한 중증도 판정과 임상적 의사결정에 이를 반영합니다.

- 12:35 - 12:50 **박출률보존심부전의 진단과 치료**
 김봉준 / 고신대의
- 12:50 - 13:05 **우심부전의 진단과 치료**
 이수용 / 부산의대
- 13:05 - 13:20 **좌심실보조장치의 이해**
 김다래 / 성균관의대
- 13:20 - 13:35 **대표적인 유전자 관련 심근증**
 이상언 / 울산의대
- 13:35 - 13:50 **심부전에 동반된 관상동맥 질환의 진단과 치료**
 김인철 / 계명대의
- 13:50 - 14:05 **Discussion**

KSOLA 3

14:25-15:55 / Rm.102

Dyslipidemia Management in Special Populations

Chairperson(s) 한기훈, 김성래
 Panel 강선미, 김학령, 양예슬, 오진경

Learning Objective

1. 고령 및 허약 노인에서 스타틴의 유익함과 위험성, 용량 조절, 중단 또는 감량 시점을 개별화해 결정하는 원칙을 이해합니다.
2. 임신 및 수유 중인 여성에서 이상지질혈증 평가, 금기약과 대체요법, 생활요법 중심 관리 전략을 체계적으로 정리합니다.
3. 암 환자에서 스타틴의 심혈관 보호효과와 악물상호작용, 수술 및 항암치료 전후 지속 또는 중단 기준을 이해하고 실제 사례에 적용합니다.

- 14:25 - 14:45 **Intensity Matters: LDL Lowering in Advanced Age and Frailty**
 구유정 / 서울의대
- 14:45 - 15:05 **Practical Lipid Care in Pregnancy**
 조인정 / 이화의대
- 15:05 - 15:25 **Oncology Meets Lipids: Statins in Cancer Care**
 정미향 / 가톨릭의대
- 15:25 - 15:55 **Discussion**

KPHS 3

14:25-15:55 / Rm.104

Genetic Insights into Pediatric Heart Disease

Chairperson(s) 허준, 이재영

Panel 권정은, 반지은, 윤자경, 조민정, 최인수

Learning Objective

소아심장질환에서 유전자 검사 적응증, 검사결과와 해석과 임상에서의 적용에 대해 살펴보는 시간입니다.

- 14:25 - 14:40 **Genetics in Congenital Heart Disease: When, Whom, and How to Evaluate**
고정민 / 서울의대
- 14:40 - 14:55 **Genetic Causes of Cardiomyopathy: Early Detection and Clinical Implications**
하기수 / 고려의대
- 14:55 - 15:10 **Inherited Arrhythmia Syndromes in Children: Variant Interpretation to Clinical Decision-Making**
송미경 / 서울의대
- 15:10 - 15:25 **Inherited Aortic Aneurysmal Disease: Genetic Mechanisms and Clinical Implications**
최희정 / 계명의대
- 15:25 - 15:40 **VUS(Variant of Unknown Significance) in Pediatric Heart Disease: Practical Approaches to Interpretation and Follow-Up**
장자현 / 성균관의대
- 15:40 - 15:55 **Discussion**

KHRS4-VT

14:25-15:55 / Rm.105

Ventricular Tachycardia

Chairperson(s) 차태준, 남기병

Panel 김도영, 김진배, 박소윤, 박형욱, 서창욱

Learning Objective

1. 다양한 심실 빈맥을 mapping 하고 ablation 할 수 있는 능력을 습득합니다.
2. 심실 빈맥의 mapping이 어려울 때 적용할 수 있는 팁을 습득합니다.
3. 약물적 치료와 시술적 치료의 장단점에 대해 이해합니다.

- 14:25 - 14:40 **My Tips for Mapping Ventricular Tachycardia Originating from Left Ventricle or Epicardium**
심재민 / 고려의대
- 14:40 - 14:55 **Mapping and Ablation of Outflow Tract Ventricular Tachycardias Not Easily Induced in EP Lab**
최영 / 가톨릭의대
- 14:55 - 15:10 **Maintaining Adequate Potassium Levels in Patients at High Risk for Ventricular Arrhythmias**
이희정 / 계명의대
- 15:10 - 15:25 **Mapping and Ablation of Hemodynamically Intolerable Ventricular Tachycardias**
김주원 / 성균관의대
- 15:25 - 15:40 **Finding P1 Potentials in ILVT Patients**
오일영 / 서울의대
- 15:40 - 15:55 **Discussion**

KSHF 3

14:25-15:55 / Rm.203

Imaging in Heart Failure Diagnosis and Treatment [Cross-Specialty]

Chairperson(s) 김응주, 고성민
Panel 김봉준, 김형윤, 이주연, 최의영

Learning Objective

1. 심부전 환자에서 Echo, Cardiac MR, CT는 상호보완적인 역할을 하면서 진단과 치료 방향 결정, 예후 평가에 중요한 역할을 하고 있어, 이 세션에서는 HF Imaging이라는 주제하에 심부전환자에서 영상진단의 적절한 활용법을 배울 수 있습니다.
2. 심부전 환자의 실제 임상환경에서 흔히 접하는 상황에 대해서 최근 업데이트된 내용을 공부하여 임상 활용할 수 있습니다.

- 14:25 - 14:40 **Distinguishing Ischemic from Non-Ischemic Dilated Cardiomyopathy: A Stepwise and Efficient Diagnostic Approach**
현준호 / 울산의대
- 14:40 - 14:55 **Cardiac MR Imaging in Myocarditis and its' Mimickers**
김영진 / 연세의대
- 14:55 - 15:10 **Diagnosis of HF with Preserved EF and Estimation of LA Pressure: What's New?**
이주희 / 충북의대
- 15:10 - 15:25 **Low Contrast or Noncontrast Imaging in HF with Renal Dysfunction**
이종은 / 울산의대
- 15:25 - 15:40 **Treatment of Ventricular Functional MR Based on Mechanisms and Imaging**
심지영 / 연세의대
- 15:40 - 15:55 **Discussion**

KSIC 4

14:25-15:55 / Rm.300B

심장내과 의사와 전공의를 위한 대퇴슬와동맥질환의 기본

Chairperson(s) 최동훈, 최승혁
Panel 김수홍, 민필기, 서준, 윤창환

Learning Objective

1. 흔하지만 심장내과 의사가 잘 모르는 말초동맥 질환 및 심부정맥 혈전증에 대해서 최고의 전문가들이 쉽게 알려드립니다. 본 세션을 통해 실제 진료에서 이러한 환자들을 보다 자신 있게 평가하고 관리하는 데 도움이 될 것입니다.
2. 말초동맥질환의 진단, 대퇴슬와동맥의 중재시술(혈관내치료)의 기본, 약물치료, 드물지만 중요한 대퇴슬와동맥관련질환과 흔한 심부정맥 혈전증에 대해서 알고 싶으시면 부담없이 오세요.

- 14:25 - 14:40 **CAD에서 PAD의 Screening이 왜 중요하며, 어떻게 진단해야 하는가?**
신상훈 / 이화의대
- 14:40 - 14:55 **초보자는 대퇴슬와동맥의 중재시술(혈관내치료)을 어떻게 준비하고 시작해야 하는가?**
원호연 / 중앙의대
- 14:55 - 15:10 **Claudication과 CLTI환자는 약물치료와 보조적 치료(재활 등)는 어떻게 해야 하는가?**
장지용 / 국민건강보험 일산병원
- 15:10 - 15:25 **드물지만 놓치면 안 되는 Nonatherosclerotic Popliteal Artery Diseases는 어떤 것이 있는가?**
윤영진 / 연세원주의대
- 15:25 - 15:40 **흔히 만나게 되는 심부정맥 혈전증은 재개통술과 약물치료 어떻게 해야 하는가?**
김지박 / 한일병원
- 15:40 - 15:55 **Discussion**

Education Workshop 4 - Echocardiography

14:25-15:55 / Rm.300C

Echocardiograph Update 2026

Chairperson(s) 조구영, 박재형

Panel 김소리, 김형섭, 손장원, 이선화

Learning Objective

1. ATTR 심근병증과 비후성 심근병증에서 심초음파를 활용한 진단 및 감별의 핵심 포인트를 이해하고, 임상에서의 역할과 가치를 인식합니다.
2. 최신 가이드라인에 근거한 이완기 기능 평가의 주요 지표와 해석 원칙을 숙지하고, 다양한 임상 상황에서 이를 실제 임상에 적용합니다.
3. 최신 판막질환 가이드라인의 주요 변화와 핵심 메시지를 이해하고, 심초음파를 기반으로 한 적절한 중증도 판정과 임상적 의사결정에 이를 반영합니다.

14:25 - 14:40 **Mastering Diastolic Function: A Practical Update Based on the Latest Guidelines**

신성희 / 인하의대

14:40 - 14:55 **Solving the Puzzle: Navigating Discordant Parameters in Grading Valvular Heart Disease**

김대희 / 울산의대

14:55 - 15:10 **Unmasking Hypertrophy: The Role of Echocardiography in Hypertrophic Cardiomyopathy**

김지훈 / 성균관대의대

15:10 - 15:25 **Echocardiography in Transthyretin Cardiac Amyloidosis: From Early Detection to Phenotyping**

문인기 / 순천향의대

15:25 - 15:40 **Management and Monitoring of ATTR-CM and HCM in the Era of New Therapies**

이현정 / 서울의대

15:40 - 15:55 **Discussion**

MEMO

MEMO

2026 춘계심혈관통합학술대회 & ACC ASIA 2026

ACC ASIA 2026 TOGETHER WITH KSC SPRING CONFERENCE


- 발행 | 2026년 4월 17일 발행
- 주최 | 대한심장학회 & 심장학연구재단
- 주관 | The Korean Society of Cardiology (KSC) 대한심장학회
American College of Cardiology (ACC) 미국심장학회
Korean Heart Rhythm Society (KHRS) 대한부정맥학회
The Korean Pediatric Heart Society (KPHS) 대한소아심장학회
The Korean Society of Heart Failure (KSHF) 대한심부전학회
Korean Society of Interventional Cardiology (KSIC) 대한심혈관중재학회
The Korean Society of Echocardiography (KSE) 한국심초음파학회
The Korean Society of Lipid and Atherosclerosis (KSoLA) 한국지질·동맥경화학회
The Korean Cardiac Research Foundation 심장학연구재단
- 발행처 | 대한심장학회
서울시 마포구 마포대로 109 롯데캐슬프레지던트 101동 1704호
Tel. 02-3275-5258 Fax. 02-3275-5259
E-mail. herz1@circulation.or.kr
- 기획제작 | 제이엠씨
서울특별시 금천구 가산동 60-25 에이스하이엔드타워6차 1201호
Tel. 02-6299-5088
E-mail. mail@jmcplan.com

* This work is supported by the 'Lottery Fund' of the 'Ministry of Strategy and Finance' and the 'Science and Technology Promotion Fund' of the 'Ministry of Science and ICT', contributing to the realization of social value and the development of national science and technology.



앱스토어에서 다운로드하세요

응급 현장의 필수 앱, ECG Buddy로 심전도를 촬영하여 분석하세요

**ECG Buddy**

식품의약품안전처 허가번호 제허24-1179호

12 유도 심전도를 스마트폰으로 촬영하여 분석하면
심장리듬을 분류하고 10가지 응급상황 및 심기능 이상과 관련된 위험도를 제공

효과적인 STEMI, ACS 스크린

- 높은 정확도로 STEMI & Equivalents를 감별하여 환자 안전을 추구
- ACS 위험도를 정량화하여 제시해 적절한 추가 평가를 진행

상세한 심장기능 평가

- 좌심실, 우심실부전 및 폐부종, 폐동맥고혈압, 심낭삼출 등을 함께 평가

고칼륨혈증 선별

- 전문의보다 더 정확하게 고칼륨혈증을 심전도로 선별하여 응급실 Triage 개선

스마트폰(카메라 촬영), 데스크탑(스크린 캡처), EMR 연동을 지원합니다.

<https://www.ecgbuddy.ai/>를 방문하여 자세한 내용을 확인해보세요.

